CA2431600A1 - Molecules with extended half-lives, compositions and uses thereof - Google Patents
Molecules with extended half-lives, compositions and uses thereof Download PDFInfo
- Publication number
- CA2431600A1 CA2431600A1 CA002431600A CA2431600A CA2431600A1 CA 2431600 A1 CA2431600 A1 CA 2431600A1 CA 002431600 A CA002431600 A CA 002431600A CA 2431600 A CA2431600 A CA 2431600A CA 2431600 A1 CA2431600 A1 CA 2431600A1
- Authority
- CA
- Canada
- Prior art keywords
- substitution
- amino acid
- igg
- modified
- threonine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 claims abstract 73
- 238000012986 modification Methods 0.000 claims abstract 45
- 230000004048 modification Effects 0.000 claims abstract 45
- 239000012634 fragment Substances 0.000 claims abstract 18
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims abstract 15
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims abstract 15
- 102000004169 proteins and genes Human genes 0.000 claims abstract 9
- 108090000623 proteins and genes Proteins 0.000 claims abstract 9
- 239000003795 chemical substances by application Substances 0.000 claims abstract 7
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract 2
- 102000018358 immunoglobulin Human genes 0.000 claims abstract 2
- 238000001727 in vivo Methods 0.000 claims abstract 2
- 238000006467 substitution reaction Methods 0.000 claims 154
- 235000001014 amino acid Nutrition 0.000 claims 70
- 229940024606 amino acid Drugs 0.000 claims 44
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 42
- 239000004473 Threonine Substances 0.000 claims 42
- 239000004475 Arginine Substances 0.000 claims 36
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 36
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 36
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 36
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 30
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 30
- 108020001507 fusion proteins Proteins 0.000 claims 27
- 102000037865 fusion proteins Human genes 0.000 claims 27
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 24
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 24
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 24
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 20
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 20
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 18
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 18
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 18
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 18
- 238000000034 method Methods 0.000 claims 18
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 15
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical group NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 12
- 239000004472 Lysine Chemical group 0.000 claims 12
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Chemical group C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 12
- 229940009098 aspartate Drugs 0.000 claims 12
- 229930195712 glutamate Chemical group 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical group OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical group OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical group OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical group C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 6
- 229960001230 asparagine Drugs 0.000 claims 6
- 235000009582 asparagine Nutrition 0.000 claims 6
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 claims 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 6
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 6
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 6
- 229930182817 methionine Natural products 0.000 claims 6
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 6
- 235000018102 proteins Nutrition 0.000 claims 6
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 230000037430 deletion Effects 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 238000003780 insertion Methods 0.000 claims 3
- 230000037431 insertion Effects 0.000 claims 3
- 239000003550 marker Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 238000009169 immunotherapy Methods 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 229940036185 synagis Drugs 0.000 claims 2
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 229940072221 immunoglobulins Drugs 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Abstract
The present invention provides molecules, including IgGs, non-IgG
immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
Claims (86)
1. A modified IgG comprising an IgG constant domain comprising one or more amino acid modifications relative to a wild-type IgG constant domain, wherein the modified IgG has an increased half life compared to the half life of an IgG having the wild-type IgG
constant domain, and wherein the one or more amino acid modifications are at one or more of positions 251, 253, 255, 285-290, 308-314, 385-389, and 428-435.
constant domain, and wherein the one or more amino acid modifications are at one or more of positions 251, 253, 255, 285-290, 308-314, 385-389, and 428-435.
2. A modified non-human IgG comprising a non-human IgG constant domain comprising one or more amino acid modifications relative to a wild-type non-human IgG
constant domain, wherein the modified IgG has an increased half life compared to the half life of an IgG having the wild-type non-human IgG constant domain, and wherein the one or more amino acid modifications are at one or more of positions 251-256, 285-290, 308-314, 385-389, and 428-436, with the proviso that the one or more amino acid modifications do not include substitution with leucine at position 252, serine at position 254, and phenylalanine at position 256.
constant domain, wherein the modified IgG has an increased half life compared to the half life of an IgG having the wild-type non-human IgG constant domain, and wherein the one or more amino acid modifications are at one or more of positions 251-256, 285-290, 308-314, 385-389, and 428-436, with the proviso that the one or more amino acid modifications do not include substitution with leucine at position 252, serine at position 254, and phenylalanine at position 256.
3. A modified human or humanized IgG comprising a human IgG constant domain comprising one or more amino acid modifications relative to a wild-type human IgG
constant domain, wherein the modified human or humanized IgG has an increased half life compared to the half life of a human or humanized IgG having the wild-type human IgG
constant domain, and wherein the one or more amino acid modifications are at one or more of positions 251-256, 285-290, 308-314, 385-389, and 428-436.
constant domain, wherein the modified human or humanized IgG has an increased half life compared to the half life of a human or humanized IgG having the wild-type human IgG
constant domain, and wherein the one or more amino acid modifications are at one or more of positions 251-256, 285-290, 308-314, 385-389, and 428-436.
4. The modified IgG according to claim 1, 2, or 3, wherein at least one of the amino acid modifications is an amino acid substitution.
5. The modified IgG according to claim 1, 2, or 3, wherein at least one of the amino acid modifications is an amino acid deletion.
6. The modified IgG according to claim 1, 2, or 3, wherein at least one of the amino acid modifications is an amino acid insertion.
7. The modified IgG according to claim 1, 2 or 3 which has a higher affinity for FcRn than the IgG having the wild-type IgG constant domain.
8. The modified IgG according to claim 7 which has a higher affinity for the FcRn at pH 6.0 than at pH 7.4.
9. The modified IgG according to claim 1, wherein said one or more amino acid modifications are amino acid substitutions at one or more of positions 251, 255, 308, 309, 311, 312, 314, 385, 386, 387, 389, 428, 433, 434, or 436.
10. The modified IgG according to claim 2 or 3, wherein said one or more amino acid modifications are amino acid substitutions at one or more of positions 251, 252, 254, 255, 256, 308, 309, 311, 312, 314, 385, 386, 387, 389, 428, 433, 434 or 336.
11. The modified IgG according to claim 1 or 3 wherein said one or more amino acid modifications are substitution with leucine at position 251, substitution with tyrosine, tryptophan or phenylalanine at position 252, substitution with threonine or serine at position 254, substitution with arginine at position 255, substitution with glutamine, arginine, serine, threonine, or glutamate at position 256, substitution with threonine at position 308, substitution with proline at position 309, substitution with serine at position 311, substitution with aspartate at position 312, substitution with leucine at position 314, substitution with arginine, aspartate or serine at position 385, substitution with threonine or proline at position 386, substitution with arginine or proline at position 387, substitution with proline, asparagine or serine at position 389, substitution with methionine or threonine at position 428, substitution with tyrosine or phenylalanine at position 434, substitution with histidine, arginine, lysine or serine at position 433, or substitution with histidine, tyrosine, arginine or threonine at position 436.
12. The modified IgG according to claim 11, wherein said one or more amino acid substitutions are substitutions with tyrosine at position 252, threonine at position 254 and glutamate at 256.
13. The modified IgG according to claim 11, wherein said one or more amino acid substitutions are substitutions with lysine at position 433, phenylalanine at position 434 and histidine at position 436.
14. The modified IgG according to claim 11, wherein said amino acid substitution is a substitution with tyrosine or tryptophan at position 252.
15. The modified IgG according to claim 2 wherein said one or more amino acid modifications are substitution with leucine at position 251, substitution with tyrosine, tryptophan or phenylaline at position 252, substitution with threonine at position 254, substitution with arginine at position 255, substitution with glutamine, arginine, serine, threonine, or glutamate at position 256, substitution with threonine at position 308, substitution with proline at position 309, substitution with serine at position 311, substitution with aspartate at position 312, substitution with leucine at position 314, substitution with arginine, aspartate or serine at position 385, substitution with threonine or proline at position 386, substitution with arginine or proline at position 387, substitution with proline, asparagine or serine at position 389, substitution with methionine or threonine at position 428, substitution with tyrosine or phenylalanine at position 434, substitution with histidine, arginine, lysine or serine at position 433, or substitution with histidine, tyrosine, arginine or threonine at position 436.
16. The modified IgG according to claim 15, wherein said one or more amino acid substitutions are substitution with tyrosine at position 252, threonine at position 254 and glutamate at 256.
17. The modified IgG according to claim 15, wherein said one or more amino acid substitutions are substitution with lysine at position 433, phenylalanine at position 434 and histidine at position 436.
18. The modified IgG according to claim 15, wherein said amino acid substitution is a substitution with tyrosine or tryptophan at position 252.
19. The modified IgG according to claim 3 or 15 which has the heavy chain variable domain and light chain variable domain of SYNAGIS®.
20. The modified IgG according to claim 3 or 15 which has the heavy chain variable domain and light chain variable domain of AFFF, p12f2, p12f4, p11d4, Ale109, A12a6, A13c4, A17d4, A4B4, A8C7, 1X-493L1FR, H3-3F4, M3H9, Y10H6, DG, AFFF(1), 6H8, L1-7E5, L215B10, A13A11, A1H5, A4B4(1), A4B4L1FR-S28R, or A4B4-F528.
21. A fusion protein comprising a non-IgG polypeptide covalently linked to a modified IgG constant domain, or a fragment thereof that binds to FcRn, said modified IgG
constant domain or fragment comprising one or more amino acid modifications relative to a wild-type IgG constant domain, wherein the one or more modifications are at one or more of positions 251, 253, 255, 285-290, 308-314, 385-389, and 428-436, and wherein said fusion protein has a longer half life than the non-IgG polypeptide alone.
constant domain or fragment comprising one or more amino acid modifications relative to a wild-type IgG constant domain, wherein the one or more modifications are at one or more of positions 251, 253, 255, 285-290, 308-314, 385-389, and 428-436, and wherein said fusion protein has a longer half life than the non-IgG polypeptide alone.
22. A fusion protein comprising a non-IgG polypeptide covalently linked to a modified non-human IgG constant domain, or a fragment thereof that binds to FcRn, said modified non-human IgG constant domain or fragment comprising one or more amino acid modifications relative to a wild-type non-human IgG constant domain, wherein the one or more modifications are at one or more of positions 251-256, 285-290, 308-314, 385-389, and 428-436, with the proviso that the modified amino acid sequence does not have leucine at position 252, serine at position 254, and phenylalanine at position 256, and wherein said fusion protein has a longer half life than the non-IgG polypeptide alone.
23. A fusion protein comprising a non-IgG polypeptide covalently linked to a modified human IgG constant domain, or a fragment thereof that binds to FcRn, said modified human IgG constant domain or fragment comprising one or more amino acid modifications relative to a wild-type human IgG constant domain, wherein the one or more modifications are at one or more of positions 251-256, 285-290, 308-314, 385-389, and 428-436, and wherein said fusion protein has a longer half life than the non-IgG
polypeptide alone.
polypeptide alone.
24. The fusion protein according to claim 21, 22, or 23, wherein at least one of the amino acid modifications is an amino acid substitution.
25. The fusion protein according to claim 21, 22, or 23, wherein at least one of the amino acid modifications is an amino acid deletion.
26. The fusion protein according to claim 21, 22, or 23, wherein at least one of the amino acid modifications is an amino acid insertion.
27. The fusion protein according to claim 21, 22, or 23, wherein the modified IgG
constant domain or fragment has an increased affinity for FcRn relative to the wild-type IgG
constant domain.
constant domain or fragment has an increased affinity for FcRn relative to the wild-type IgG
constant domain.
28. The fusion protein according to claim 27, wherein the modified IgG
constant domain or fragment has a higher affinity for the FcRn at pH 6.0 than at pH
7.4.
constant domain or fragment has a higher affinity for the FcRn at pH 6.0 than at pH
7.4.
29. The fusion protein according to claim 21, 22, or 23, wherein the non-IgG
polypeptide is an immunoglobulin.
polypeptide is an immunoglobulin.
30. The fusion protein according to claim 21, wherein the one or more amino acid modifications are amino acid substitutions at one or more of positions 251, 255, 308, 309, 311, 312, 314, 385, 386, 387, 389, 428, 433, 434, or 436.
31. The fusion protein according to claim 22 or 23, wherein the one or more amino acid modifications are amino acid substitutions at one or more of positions 251, 252, 254, 255, 256, 308, 309, 311, 312, 314, 385, 386, 387, 389, 428, 433, 434 or 336.
32. The fusion protein according to claim 21 or 23, wherein said one or more amino acid modifications are substitution with leucine at position 251, substitution with tyrosine, tryptophan or phenylalanine at position 252, substitution with threonine or serine at position 254, substitution with arginine at position 255, substitution with glutamine, arginine, serine, threonine, or glutamate at position 256, substitution with threonine at position 308, substitution with proline at position 309, substitution with serine at position 311, substitution with aspartate at position 312, substitution with leucine at position 314, substitution with arginine, aspartate or serine at position 385, substitution with threonine or proline at position 386, substitution with arginine or proline at position 387, substitution with proline, asparagine or serine at position 389, substitution with methionine or threonine at position 428, substitution with tyrosine or phenylalanine at position 434, substitution with histidine, arginine, lysine or serine at position 433, or substitution with histidine, tyrosine, arginine or threonine at position 436.
33. The fusion protein according to claim 32, wherein said one or more amino acid substitutions are substitutions with tyrosine at position 252, threonine at position 254 and glutamate at 256.
34. The fusion protein according to claim 32, wherein said one or more amino acid substitutions are substitutions with lysine at position 433, phenylalanine at position 434 and histidine at position 436.
35. The fusion protein according to claim 32, wherein said amino acid substitution is a substitution with tyrosine or tryptophan at position 252.
36. The fusion protein according to claim 32, wherein said one or more amino acid modifications are substitution with leucine at position 251, substitution with tyrosine, tryptophan or phenylalanine at position 252, substitution with threonine at position 254, substitution with arginine at position 255, substitution with glutamine, arginine, serine, threonine, or glutamate at position 256, substitution with threonine at position 308, substitution with proline at position 309, substitution with serine at position 311, substitution with aspartate at position 312, substitution with leucine at position 314, substitution with arginine, aspartate or serine at position 385, substitution with threonine or proline at position 386, substitution with arginine or proline at position 387, substitution with proline, asparagine or serine at position 389, substitution with methionine or threonine at position 428, substitution with tyrosine or phenylalanine at position 434, substitution with histidine, arginine, lysine or serine at position 433, or substitution with histidine, tyrosine, arginine or threonine at position 436.
37. The fusion protein according to claim 36, wherein said one or more amino acid substitutions are substitutions with tyrosine at position 252, threonine at position 254 and glutamate at 256.
38. The fusion protein according to claim 36, wherein said one or more amino acid substitutions are substitutions with lysine at position 433, phenylalanine at position 434 and histidine at position 436.
39. The fusion protein according to claim 36, wherein said amino acid substitution is a substitution with tyrosine or tryptophan at position 252.
40. A molecule comprising a non-protein agent conjugated to a modified IgG
constant domain, or a fragment thereof that binds to FcRn, said modified IgG
constant domain or fragment comprising one or more amino acid modifications relative to a wild-type IgG constant domain, wherein the one or more modifications are at one or more of positions 251, 253, 255, 285-290, 308-314, 385-389, and 428-436, and wherein said molecule has a longer half life than the non-protein agent alone.
constant domain, or a fragment thereof that binds to FcRn, said modified IgG
constant domain or fragment comprising one or more amino acid modifications relative to a wild-type IgG constant domain, wherein the one or more modifications are at one or more of positions 251, 253, 255, 285-290, 308-314, 385-389, and 428-436, and wherein said molecule has a longer half life than the non-protein agent alone.
41. A molecule comprising a non-protein agent conjugated to a modified non-human IgG constant domain, or a fragment thereof that binds to FcRn, said modified non-human IgG constant domain or fragment comprising one or more amino acid modifications relative to a wild-type non-human IgG constant domain, wherein the one or more modifications are at one or more of positions 251-256, 285-290, 308-314, 385-389, and 428-436, with the proviso that the modified amino acid sequence does not have leucine at position 252, serine at position 254, and phenylalanine at position 256, and wherein said molecule has a longer half life than the non-protein agent alone.
42. A molecule comprising a non-protein agent conjugated to a modified human IgG constant domain, or a fragment thereof that binds to FcRn, said modified human IgG
constant domain or fragment comprising one or more amino acid modifications relative to a wild-type human IgG constant domain, wherein the one or more modifications are at one or more of positions 251-256, 285-290, 308-314, 385-389, and 428-436, and wherein said molecule has a longer half life than the non-protein agent alone.
constant domain or fragment comprising one or more amino acid modifications relative to a wild-type human IgG constant domain, wherein the one or more modifications are at one or more of positions 251-256, 285-290, 308-314, 385-389, and 428-436, and wherein said molecule has a longer half life than the non-protein agent alone.
43. The molecule according to claim 40, 41, or 42 wherein at least one of the amino acid modifications is an amino acid substitution.
44. The molecule according to claim 40, 41, or 42 wherein at least one of the amino acid modifications is an amino acid deletion.
45. The molecule according to claim 40, 41 or 42, wherein at least one of the amino acid modifications is an amino acid insertion.
46. The molecule according to claim 40, 41 or 42, wherein the modified IgG
constant domain or fragment has an increased affinity fox FcRn relative to the wild-type constant domain.
constant domain or fragment has an increased affinity fox FcRn relative to the wild-type constant domain.
47. The molecule according to claim 46, wherein the modified IgG constant domain or fragment has a higher affinity for the FcRn at pH 6.0 than at pH
7.4.
7.4.
48. The molecule according to claim 40, wherein the one or more amino acid modifications are amino acid substitutions at one or more of positions 251, 255, 308, 309, 311, 312, 314, 385, 386, 387, 389, 428, 433, 434, or 436.
49. The molecule according to claim 41 or 42, wherein the one or more amino acid modifications are substitution at one or more of positions 251, 252, 254, 255, 256, 308, 309, 311, 312, 314, 385, 386, 387, 389, 428, 433, 434 or 336.
50. The molecule according to claim 40 or 42, wherein said one or more amino acid modifications are substitution with leucine at position 251, substitution with tyrosine, tryptophan or phenylalanine at position 252, substitution with threonine or serine at position 254, substitution with arginine at position 255, substitution with glutamine, arginine, serine, threonine, or glutamate at position 256, substitution with threonine at position 308, substitution with proline at position 309, substitution with serine at position 311, substitution with aspartate at position 312, substitution with leucine at position 314, substitution with arginine, aspartate or serine at position 385, substitution with threonine or proline at position 386, substitution with arginine or proline at position 387, substitution with proline, asparagine or serine at position 389, substitution with methionine or threonine at position 428, substitution with tyrosine or phenylalanine at position 434, substitution with histidine, arginine, lysine or serine at position 433, or substitution with histidine, tyrosine, arginine or threonine at position 436.
51. The molecule according to claim 50, wherein said one or more amino acid substitutions are substitutions with tyrosine at position 252, threonine at position 254 and glutamate at 256.
52. The molecule according to claim 50, wherein said one or more amino acid substitutions are substitutions with lysine at position 433, phenylalanine at position 434 and histidine at position 436.
53. The molecule according to claim 50, wherein said amino acid substitution is a substitution with tyrosine or tryptophan at position 252.
54. The molecule according to claim 41, wherein said one or more amino acid modifications are substitution with leucine at position 251, substitution with tyrosine, tryptophan or phenylalanine at position 252, substitution with threonine at position 254, substitution with arginine at position 255, substitution with glutamine, arginine, serine, threonine, or glutamate at position 256, substitution with threonine at position 308, substitution with proline at position 309, substitution with serine at position 311, substitution with aspartate at position 312, substitution with leucine at position 314, substitution with arginine, aspartate or serine at position 385, substitution with threonine or proline at position 386, substitution with arginine or proline at position 387, substitution with proline, asparagine or serine at position 389, substitution with methionine or threonine at position 428, substitution with tyrosine or phenylalanine at position 434, substitution with histidine, arginine, lysine or serine at position 433, or substitution with histidine, tyrosine, arginine or threonine at position 436.
55. The molecule according to claim 54, wherein said one or more amino acid substitutions are substitutions with tyrosine at position 252, threonine at position 254 and glutamate at 256.
56. The molecule according to claim 54, wherein said one or more amino acid substitutions are substitutions with lysine at position 433, phenylalanine at position 434 and histidine at position 436.
57. The molecule according to claim 54, wherein said amino acid substitution is a substitution with tyrosine or tryptophan at position 252.
58. A pharmaceutical composition comprising the modified human or humanized IgG according to claim 3 and a pharmaceutically acceptable carrier.
59. A pharmaceutical composition comprising the fusion protein according to claim 23 and a pharmaceutically acceptable carrier.
60. A pharmaceutical composition comprising the molecule according to claim 42 and a pharmaceutically acceptable carrier.
61. A method of treating a disease or disorder comprising administering to a patient in need thereof a therapeutically effective amount of the modified human or humanized IgG according to claim 3.
62. The method according to claim 61 which comprises passive immunotherapy.
63. A method of treating a disease or disorder comprising administering to a patient in need thereof a therapeutically effective amount of the fusion protein according to claim 23.
64. A method of treating a disease or disorder comprising administering to a patient in need thereof a therapeutically effective amount of the molecule according to claim 42.
65. A nucleic acid comprising a nucleotide sequence encoding the modified IgG
constant domain according to claim 1, 2 or 3, or an FcRn binding fragment thereof.
constant domain according to claim 1, 2 or 3, or an FcRn binding fragment thereof.
66. A nucleic acid comprising a nucleotide sequence encoding the fusion protein according to claim 21, 22, or 23.
67. A host cell comprising the nucleic acid according to claim 65.
68. A host cell comprising the nucleic acid according to claim 66.
69. A kit comprising the modified human or humanized IgG according to claim 3.
70. A kit comprising the fusion protein according to claim 23.
71. A kit comprising the molecule according to claim 42.
72. A method of preventing a disease or disorder comprising administering to a subject a prophylactically effective amount of the modified human or humanized IgG
according to claim 3.
according to claim 3.
73. The method according to claim 72 which is passive immunotherapy.
74. The method according to claim 72 wherein the disease is RSV infection.
75. The method according to claim 74, wherein said modified human or humanized IgG is a modified SYNAGIS® antibody.
76. The method according to claim 74, wherein said modified human or humanized IgG is a modified AFFF, p 12f2, p 12f4, p11d4, Ale109, A12a6, A13c4, A17d4, A4B4, A8C7, 1X-493L1FR, H3-3F4, M3H9, Y10H6, DG, AFFF(1), 6H8, L1-7E5, L215B10, A13A11, A1H5, A4B4(1), A4B4L1FR-S28R or A4B4-F52S antibody.
77. A method of vaccinating a subject comprising administering to said subject an amount of the modified human or humanized IgG according to claim 3 effective to elicit an immune response.
78. A method of vaccinating a subject comprising administering to said subject an amount of the fusion protein according to claim 23 effective to elicit an immune response.
79. The method according to 61 which comprises administrating a dose of said modified human or humanized IgG that is lower than the lowest therapeutically effective dose of a second IgG identical to said modified human or humanized IgG except that said second IgG lacks said one or more amino acid modifications.
80. The method according to claim 79 which results in fewer or less severe side effects than administration of the therapeutically effective dose of the second IgG.
81. The method according to claim 61 which comprises administering a therapeutically effective dosing schedule having less frequent doses of said modified human or humanized IgG than the therapeutically effective dosing schedule having the least frequent dosing of a second IgG identical to said modified human or humanized IgG
except that said second IgG lacks said one or more amino acid modifications.
except that said second IgG lacks said one or more amino acid modifications.
82. The method according to claim 72 which comprises administrating a prophylactically effective dose of said modified human or humanized IgG that is lower than the lowest prophylactically effective dose of a second IgG identical to said modified human or humanized IgG except that said second IgG lacks said one or more amino acid modifications.
83. The method according to claim 82 which results in fewer or less severe side effects than administration of the prophylactically effective dose of the second IgG.
84. The method according to claim 72 which comprises administering a prophylactically effective dosing schedule having less frequent doses of said modified human or humanized IgG than the prophylactically effective dosing schedule with the least frequent dosing of a second IgG identical to said humani or humanized IgG except that said second IgG lacks said one or more amino acid modifications.
85. A method of in vivo diagnosis in a subject comprising:
(a) administering to a subject an effective amount of the modified human or humanized IgG according to claim 3 labeled with a detectable marker, said modified human or humanized IgG specifically binding to an antigen associated with a disease or disorder;
(b) allowing the modified human or humanized IgG to concentrate at sites in said subject where said antigen is found; and (c) detecting said detectable marker, whereby detection of said detectable marker above a background or standard level indicates that the subject has said disease or disorder.
(a) administering to a subject an effective amount of the modified human or humanized IgG according to claim 3 labeled with a detectable marker, said modified human or humanized IgG specifically binding to an antigen associated with a disease or disorder;
(b) allowing the modified human or humanized IgG to concentrate at sites in said subject where said antigen is found; and (c) detecting said detectable marker, whereby detection of said detectable marker above a background or standard level indicates that the subject has said disease or disorder.
86. The modified human or humanized IgG according to claim 3 which immunospecifically binds to an RSV antigen.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2766160A CA2766160A1 (en) | 2000-12-12 | 2001-12-12 | Modified molecules with increased affinity for fcrn, compositions, and uses thereof |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25488400P | 2000-12-12 | 2000-12-12 | |
US60/254,884 | 2000-12-12 | ||
US28976001P | 2001-05-09 | 2001-05-09 | |
US60/289,760 | 2001-05-09 | ||
PCT/US2001/048432 WO2002060919A2 (en) | 2000-12-12 | 2001-12-12 | Molecules with extended half-lives, compositions and uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2766160A Division CA2766160A1 (en) | 2000-12-12 | 2001-12-12 | Modified molecules with increased affinity for fcrn, compositions, and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2431600A1 true CA2431600A1 (en) | 2002-08-08 |
CA2431600C CA2431600C (en) | 2012-04-17 |
Family
ID=26944296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2431600A Expired - Lifetime CA2431600C (en) | 2000-12-12 | 2001-12-12 | Molecules with extended half-lives, compositions and uses thereof |
Country Status (12)
Country | Link |
---|---|
US (8) | US7083784B2 (en) |
EP (5) | EP2341060B1 (en) |
JP (7) | JP4336498B2 (en) |
AT (1) | ATE489395T1 (en) |
AU (1) | AU2002248184C1 (en) |
CA (1) | CA2431600C (en) |
CY (1) | CY1111283T1 (en) |
DE (1) | DE60143544D1 (en) |
DK (1) | DK1355919T3 (en) |
ES (2) | ES2727425T3 (en) |
PT (1) | PT1355919E (en) |
WO (1) | WO2002060919A2 (en) |
Families Citing this family (762)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
US6656467B2 (en) * | 2000-01-27 | 2003-12-02 | Medimmune, Inc. | Ultra high affinity neutralizing antibodies |
ES2390761T3 (en) | 2000-03-01 | 2012-11-16 | Medimmune, Llc | Recombinant high-potency antibodies and method for their production |
US7179900B2 (en) * | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
US6855493B2 (en) | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
EP2341060B1 (en) * | 2000-12-12 | 2019-02-20 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
US7658921B2 (en) * | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
US20040002587A1 (en) * | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20100311954A1 (en) * | 2002-03-01 | 2010-12-09 | Xencor, Inc. | Optimized Proteins that Target Ep-CAM |
US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
US20080254027A1 (en) * | 2002-03-01 | 2008-10-16 | Bernett Matthew J | Optimized CD5 antibodies and methods of using the same |
US20090042291A1 (en) * | 2002-03-01 | 2009-02-12 | Xencor, Inc. | Optimized Fc variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20070148171A1 (en) * | 2002-09-27 | 2007-06-28 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US20050152899A1 (en) * | 2002-05-10 | 2005-07-14 | Kinch Michael S. | EphA2 agonistic monoclonal antibodies and methods of use thereof |
JP4557714B2 (en) | 2002-05-10 | 2010-10-06 | メディミューン,エルエルシー | EphA2 monoclonal antibody and method of use thereof |
WO2004014292A2 (en) * | 2002-05-10 | 2004-02-19 | Purdue Research Foundation | EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF |
US7425618B2 (en) * | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
US8946387B2 (en) | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8968730B2 (en) | 2002-08-14 | 2015-03-03 | Macrogenics Inc. | FcγRIIB specific antibodies and methods of use thereof |
US20060235208A1 (en) * | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
PT1562972E (en) * | 2002-10-15 | 2010-11-10 | Facet Biotech Corp | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
US7361740B2 (en) * | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7365168B2 (en) * | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7217797B2 (en) * | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
EP2368578A1 (en) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
EP2272533A1 (en) | 2003-01-13 | 2011-01-12 | MacroGenics, Inc. | Soluble FcyR fusion proteins and methods of use thereof |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
JP4685764B2 (en) * | 2003-04-10 | 2011-05-18 | アボット バイオセラピューティクス コーポレイション | Modification of antibody FcRn binding affinity or serum half-life by mutagenesis |
WO2004091375A2 (en) * | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Epha2 and non-neoplastic hyperproliferative cell disorders |
KR101224235B1 (en) | 2003-04-11 | 2013-01-25 | 메디뮨 엘엘씨 | Recombinant IL-9 Antibodies and Uses Thereof |
US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
DE602004029252D1 (en) * | 2003-06-13 | 2010-11-04 | Biogen Idec Inc | AGLYCOSYL-ANTI-CD154 (CD40-LIGAND) ANTIBODIES AND THEIR USES |
JP4178514B2 (en) * | 2003-06-27 | 2008-11-12 | 東洋紡績株式会社 | Antibody screening method |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
CN1871259A (en) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | Improved antibodies having altered effector function and methods for making the same |
WO2005019434A2 (en) | 2003-08-26 | 2005-03-03 | The Regents Of The University Of Colorado, A Body Corporate | Serine protease inhibitors for treatment of bacterial infections |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
CA2545539A1 (en) | 2003-10-15 | 2005-04-28 | Pdl Biopharma, Inc. | Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig |
CA2545603A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
WO2005063815A2 (en) * | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
WO2005077981A2 (en) * | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
EP2053062A1 (en) * | 2004-03-24 | 2009-04-29 | Xencor, Inc. | Immunoglobin variants outside the Fc region |
EP1755673B1 (en) | 2004-04-12 | 2014-07-23 | MedImmune, LLC | Anti-il-9 antibody formulations and uses thereof |
NZ551180A (en) | 2004-06-01 | 2009-10-30 | Genentech Inc | Antibody drug conjugates and methods |
US20150010550A1 (en) | 2004-07-15 | 2015-01-08 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
EP1791563A4 (en) | 2004-07-26 | 2009-07-08 | Biogen Idec Inc | Anti-cd154 antibodies |
EA012464B1 (en) | 2004-08-04 | 2009-10-30 | Эпплайд Молекьюлар Эволюшн, Инк. | Antibody against cd20 and use thereof |
AU2005277567A1 (en) * | 2004-08-16 | 2006-03-02 | Medimmune, Llc | Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity |
CA2577133A1 (en) * | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
US20060074225A1 (en) * | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
CA2585717A1 (en) | 2004-10-27 | 2006-05-04 | Medimmune Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
EP1812068A4 (en) * | 2004-10-29 | 2010-06-09 | Medimmune Inc | Methods of preventing and treating rsv infections and related conditions |
US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
US20070135620A1 (en) * | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
CN102746404B (en) * | 2004-11-12 | 2016-01-20 | 赞科股份有限公司 | To FcRn in conjunction with reformed Fc variant |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
ATE425186T1 (en) | 2005-01-05 | 2009-03-15 | F Star Biotech Forsch & Entw | SYNTHETIC IMMUNOGLOBULIN DOMAINS WITH BINDING PROPERTIES MODIFIED IN REGIONS OF THE MOLECULE DIFFERENT FROM THE AREAS DETERMINING COMPLEMENTARITY |
WO2006076594A2 (en) * | 2005-01-12 | 2006-07-20 | Xencor, Inc. | Antibodies and fc fusion proteins with altered immunogenicity |
AU2006206187B2 (en) * | 2005-01-24 | 2011-03-10 | Board Of Regents, The University Of Texas System | Fc-fusion constructs binding to phosphatidylserine and their therapeutic use |
US20060233791A1 (en) | 2005-02-15 | 2006-10-19 | Duke University | Anti-CD19 antibodies and uses in oncology |
WO2006130201A1 (en) | 2005-03-14 | 2006-12-07 | Board Of Regents, The University Of Texas System | Antigene oligomers inhibit transcription |
US10011858B2 (en) | 2005-03-31 | 2018-07-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
CA2605024C (en) | 2005-04-15 | 2018-05-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US11254748B2 (en) | 2005-04-15 | 2022-02-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
CA2606102C (en) | 2005-04-26 | 2014-09-30 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
EP1885755A4 (en) | 2005-05-05 | 2009-07-29 | Univ Duke | Anti-cd19 antibody therapy for autoimmune disease |
MX2007013609A (en) | 2005-05-06 | 2008-01-24 | Zymogenetics Inc | Il-31 monoclonal antibodies and methods of use. |
US8163881B2 (en) | 2005-05-31 | 2012-04-24 | The Board Of Regents Of The University Of Texas System | Immunoglobulin molecules with improved characteristics |
WO2007094842A2 (en) | 2005-12-02 | 2007-08-23 | Genentech, Inc. | Binding polypeptides and uses thereof |
AU2006265936A1 (en) * | 2005-07-01 | 2007-01-11 | Medimmune, Llc | An integrated approach for generating multidomain protein therapeutics |
WO2007008943A2 (en) | 2005-07-08 | 2007-01-18 | Xencor, Inc. | Optimized anti-ep-cam antibodies |
SI2573114T1 (en) | 2005-08-10 | 2016-08-31 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
EP1931709B1 (en) | 2005-10-03 | 2016-12-07 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
CA2625998C (en) | 2005-10-06 | 2015-12-01 | Xencor, Inc. | Optimized anti-cd30 antibodies |
KR20080073293A (en) | 2005-10-14 | 2008-08-08 | 메디뮨 엘엘씨 | Cell display of antibody libraries |
ES2577292T3 (en) | 2005-11-07 | 2016-07-14 | Genentech, Inc. | Binding polypeptides with diversified VH / VL hypervariable sequences and consensus |
EP1957648B1 (en) | 2005-11-17 | 2014-04-23 | Board of Regents, The University of Texas System | Modulation of gene expression by oligomers targeted to chromosomal dna |
EP2805971A1 (en) | 2005-11-28 | 2014-11-26 | ZymoGenetics, Inc. | IL-21 antagonists |
EP1973576B1 (en) * | 2005-11-28 | 2019-05-15 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
AU2007212147A1 (en) * | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
EP2540741A1 (en) | 2006-03-06 | 2013-01-02 | Aeres Biomedical Limited | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
DK3056568T3 (en) | 2006-03-31 | 2021-11-01 | Chugai Pharmaceutical Co Ltd | PROCEDURES FOR CONTROL OF THE BLOOD PHARMACOKINETICS OF ANTIBODIES |
ES2654040T3 (en) | 2006-03-31 | 2018-02-12 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for the purification of bispecific antibodies |
AR060978A1 (en) | 2006-05-30 | 2008-07-23 | Genentech Inc | ANTIBODIES AND IMMUNOCATE PLAYERS AND THEIR USES |
EP2032159B1 (en) | 2006-06-26 | 2015-01-07 | MacroGenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
LT2029173T (en) | 2006-06-26 | 2016-11-10 | Macrogenics, Inc. | Fc riib-specific antibodies and methods of use thereof |
AT503889B1 (en) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | MULTIVALENT IMMUNE LOBULINE |
AT503902B1 (en) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | METHOD FOR MANIPULATING IMMUNE LOBULINS |
AT503861B1 (en) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | METHOD FOR MANIPULATING T-CELL RECEPTORS |
CL2007002225A1 (en) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A |
CN101553505B (en) | 2006-08-03 | 2013-07-17 | 阿斯利康(瑞典)有限公司 | Antibodies directed to alphaVbeta6 and uses thereof |
RU2009107494A (en) | 2006-08-04 | 2010-09-10 | Астразенека Аб (Se) | ANTIBODIES TO ErbB2 |
DK2383297T5 (en) | 2006-08-14 | 2022-07-04 | Xencor Inc | Optimized antibodies directed against CD19 |
CN101522713A (en) | 2006-09-01 | 2009-09-02 | 津莫吉尼蒂克斯公司 | Variable region sequences of IL-31 monoclonal antibodies and methods of use |
MX2009002414A (en) | 2006-09-08 | 2009-05-20 | Medimmune Llc | Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease. |
WO2008036688A2 (en) | 2006-09-18 | 2008-03-27 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
JP2010506842A (en) * | 2006-10-16 | 2010-03-04 | メディミューン,エルエルシー | Molecules with reduced half-life, compositions thereof and uses |
SI2502938T1 (en) | 2006-10-27 | 2015-05-29 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
EP2687232A1 (en) | 2006-12-06 | 2014-01-22 | MedImmune, LLC | Methods of treating systemic lupus erythematosus |
US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
SG10201503407WA (en) | 2006-12-19 | 2015-06-29 | Genentech Inc | Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
US8637016B2 (en) | 2007-03-08 | 2014-01-28 | Kalobios Pharmaceuticals, Inc. | EphA3 antibodies for the treatment of solid tumors |
EP1980269A1 (en) * | 2007-04-13 | 2008-10-15 | Katholieke Universiteit Leuven | Prevention of staphylococcus biofilm formation |
RU2549701C2 (en) | 2007-05-07 | 2015-04-27 | Медиммун, Ллк | Anti-icos antibodies and their application in treatment of oncological, transplantation-associated and autoimmune diseases |
LT2176298T (en) | 2007-05-30 | 2018-04-10 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
EP1997830A1 (en) * | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
US7580304B2 (en) * | 2007-06-15 | 2009-08-25 | United Memories, Inc. | Multiple bus charge sharing |
JP5602625B2 (en) | 2007-06-26 | 2014-10-08 | エフ−スター ビオテヒノロギッシェ フォルシュングス− ウント エントヴィッケルングスゲゼルシャフト ミット ベシュレンクテル ハフツング | Binding substance display |
US20110077383A1 (en) * | 2007-07-03 | 2011-03-31 | Medimmune, Llc | Hinge domain engineering |
JP2010535032A (en) | 2007-07-31 | 2010-11-18 | メディミューン,エルエルシー | Multispecific epitope binding proteins and uses thereof |
PE20120259A1 (en) | 2007-08-09 | 2012-04-04 | Boehringer Ingelheim Int | ANTI-CD37 ANTIBODIES |
EP2190987B1 (en) * | 2007-08-21 | 2012-11-14 | MorphoSys AG | Methods for the formation of disulphide bonds |
CN106519025B (en) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | Method for changing isoelectric point of antibody by using amino acid substitution of CDR |
CL2008002886A1 (en) | 2007-09-26 | 2009-12-04 | Chugai Pharmaceutical Co Ltd | Constant region of a human antibody; anti-interleukin-6 (yl-6) receptor antibody and pharmaceutical composition comprising it. |
AU2008324800B2 (en) | 2007-11-05 | 2014-03-27 | Astrazeneca Ab | Methods of treating scleroderma |
JP5809415B2 (en) | 2007-11-09 | 2015-11-10 | ペレグリン ファーマシューティカルズ,インコーポレーテッド | Compositions and methods of anti-VEGF antibodies |
US7883700B2 (en) | 2007-12-07 | 2011-02-08 | Zymogenetics, Inc. | Anti-human IL-21 monoclonal antibodies |
US8470979B2 (en) | 2007-12-07 | 2013-06-25 | Zymogenetics, Inc. | Humanized antibody molecules specific for IL-31 |
US8795667B2 (en) | 2007-12-19 | 2014-08-05 | Macrogenics, Inc. | Compositions for the prevention and treatment of smallpox |
US8092804B2 (en) * | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
RU2490278C2 (en) | 2007-12-21 | 2013-08-20 | Медиммун Лимитед | ELEMENT BOUND WITH INTERLEUKIN-4 RECEPTOR α (IL-4Rα)-173 |
SI2808343T1 (en) | 2007-12-26 | 2019-10-30 | Xencor Inc | Fc variants with altered binding to FcRn |
AU2009205995B2 (en) | 2008-01-18 | 2014-04-03 | Medimmune, Llc | Cysteine engineered antibodies for site-specific conjugation |
EP2080770A1 (en) * | 2008-01-21 | 2009-07-22 | MorphoSys AG | Proteinaceous binding molecules comprising purification tags |
CN101952454B (en) | 2008-02-08 | 2014-06-04 | 米迪缪尼有限公司 | Anti-IFNAR1 antibodies with reduced Fc ligand affinity |
WO2009123894A2 (en) | 2008-04-02 | 2009-10-08 | Macrogenics, Inc. | Her2/neu-specific antibodies and methods of using same |
ES2654937T3 (en) | 2008-04-02 | 2018-02-15 | Macrogenics, Inc. | Specific antibodies for the BCR complex and procedures for their use |
KR102469853B1 (en) | 2008-04-11 | 2022-11-22 | 추가이 세이야쿠 가부시키가이샤 | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US8314213B2 (en) * | 2008-04-18 | 2012-11-20 | Xencor, Inc. | Human equivalent monoclonal antibodies engineered from nonhuman variable regions |
EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
US8834875B2 (en) | 2010-01-13 | 2014-09-16 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
TW201016233A (en) * | 2008-07-15 | 2010-05-01 | Genentech Inc | Methods of treating autoimmune diseases using CD4 antibodies |
EP2927244A1 (en) | 2008-09-19 | 2015-10-07 | MedImmune, LLC | Antibodies directed to DLL4 and uses thereof |
TWI440469B (en) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
KR20190025057A (en) * | 2008-10-14 | 2019-03-08 | 제넨테크, 인크. | Immunoglobulin variants and uses thereof |
US8298533B2 (en) | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
US20110293605A1 (en) | 2008-11-12 | 2011-12-01 | Hasige Sathish | Antibody formulation |
EP2752189B1 (en) | 2008-11-22 | 2016-10-26 | F. Hoffmann-La Roche AG | Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer |
US8775090B2 (en) | 2008-12-12 | 2014-07-08 | Medimmune, Llc | Crystals and structure of a human IgG Fc variant with enhanced FcRn binding |
EP2379595A2 (en) | 2008-12-23 | 2011-10-26 | AstraZeneca AB | Targeted binding agents directed to 5 1 and uses thereof |
US20120003235A1 (en) | 2008-12-31 | 2012-01-05 | Biogen Idec Ma Inc. | Anti-lymphotoxin antibodies |
KR20110108398A (en) * | 2009-01-29 | 2011-10-05 | 메디뮨 엘엘씨 | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
CN102405237A (en) | 2009-03-06 | 2012-04-04 | 卡罗拜奥斯制药公司 | Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3 |
EP2406399B1 (en) | 2009-03-09 | 2018-02-14 | Bioatla, LLC | Mirac proteins |
EA024695B1 (en) | 2009-03-16 | 2016-10-31 | Сефалон Острэйлиа Пти Лтд. | Humanised antibodies with anti-tumour activity |
JP5787446B2 (en) | 2009-03-19 | 2015-09-30 | 中外製薬株式会社 | Antibody constant region variants |
WO2010107110A1 (en) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | Antibody constant region variant |
EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
CA2754163C (en) | 2009-03-25 | 2019-04-09 | Genentech, Inc. | Anti-fgfr3 antibodies and methods using same |
SG10201401604VA (en) | 2009-04-20 | 2014-08-28 | Oxford Biotherapeutics Ltd | Antibodies Specific To Cadherin-17 |
WO2010141329A1 (en) | 2009-06-01 | 2010-12-09 | Medimmune, Llc | Molecules with extended half-lives and uses thereof |
WO2011005481A1 (en) | 2009-06-22 | 2011-01-13 | Medimmune, Llc | ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION |
US8568719B2 (en) | 2009-08-13 | 2013-10-29 | Crucell Holland B.V. | Antibodies against human respiratory syncytial virus (RSV) and methods of use |
WO2011020024A2 (en) | 2009-08-13 | 2011-02-17 | The Johns Hopkins University | Methods of modulating immune function |
WO2011022264A1 (en) | 2009-08-15 | 2011-02-24 | Genentech, Inc. | Anti-angiogenesis therapy for the treatment of previously treated breast cancer |
CN102741422B (en) | 2009-08-24 | 2016-06-08 | 阿穆尼克斯运营公司 | Factor VII composition and preparation and application thereof |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
JP2013504585A (en) | 2009-09-09 | 2013-02-07 | セントローズ, エルエルシー | Extracellular targeted drug complex |
US20110189183A1 (en) | 2009-09-18 | 2011-08-04 | Robert Anthony Williamson | Antibodies against candida, collections thereof and methods of use |
WO2011037158A1 (en) | 2009-09-24 | 2011-03-31 | 中外製薬株式会社 | Modified antibody constant regions |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
US9096877B2 (en) | 2009-10-07 | 2015-08-04 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
EP2470569A1 (en) | 2009-10-13 | 2012-07-04 | Oxford Biotherapeutics Ltd. | Antibodies against epha10 |
CA2777068C (en) | 2009-10-14 | 2020-05-26 | Kalobios Pharmaceuticals, Inc. | Antibodies to epha3 |
NZ599337A (en) | 2009-10-22 | 2013-05-31 | Genentech Inc | Anti-hepsin antibodies and methods using same |
BR112012010202A2 (en) | 2009-11-02 | 2015-09-22 | Univ Washington | dimeric polypeptide hybrid nuclease molecule, pharmaceutical composition nucleic acid molecule recombinant expression vector transformed host cell method for preparing the nuclease molecule and method for treating or preventing a condition associated with an abnormal immune |
AU2010315101B2 (en) | 2009-11-04 | 2016-01-28 | Fabrus Llc | Methods for affinity maturation-based antibody optimization |
RU2585488C2 (en) | 2009-11-05 | 2016-05-27 | Дженентек, Инк. | Methods and composition for secretion of heterologous polypeptides |
CN102740885B (en) | 2009-11-05 | 2015-04-01 | 梯瓦制药澳大利亚私人有限公司 | Treatment of cancer involving mutated kras or braf genes |
US8881354B2 (en) | 2009-11-16 | 2014-11-11 | Jtekt Corporation | Tool radius adjusting system for boring holder, tool radius adjusting method in machine tool, and machine tool |
NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
US9023996B2 (en) | 2009-12-23 | 2015-05-05 | Synimmune Gmbh | Anti-FLT3 antibodies |
TWI535445B (en) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt antagonists and methods of treatment and screening |
US8362210B2 (en) | 2010-01-19 | 2013-01-29 | Xencor, Inc. | Antibody variants with enhanced complement activity |
WO2011089211A1 (en) | 2010-01-22 | 2011-07-28 | Synimmune Gmbh | Anti-cd133 antibodies and methods of using the same |
CN102933231B (en) | 2010-02-10 | 2015-07-29 | 伊缪诺金公司 | CD20 antibody and uses thereof |
WO2011102845A1 (en) * | 2010-02-18 | 2011-08-25 | Transtech Pharma, Inc. | Rage fusion protein compositions and methods of use |
AU2011221229B2 (en) | 2010-02-23 | 2015-06-18 | F. Hoffmann-La Roche Ag | Anti-angiogenesis therapy for the treatment of ovarian cancer |
CN103805202B (en) | 2010-02-25 | 2018-05-18 | 旭化成株式会社 | Copper oxide etching solution and use its engraving method |
ME03447B (en) | 2010-03-04 | 2020-01-20 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
US10435458B2 (en) | 2010-03-04 | 2019-10-08 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variants with reduced Fcgammar binding |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
US8642557B2 (en) | 2010-03-12 | 2014-02-04 | Abbvie Biotherapeutics Inc. | CTLA4 proteins and their uses |
TWI667257B (en) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | Antibodies with modified affinity to fcrn that promote antigen clearance |
NZ629829A (en) | 2010-04-30 | 2015-11-27 | Alexion Pharma Inc | Anti-c5a antibodies and methods for using the antibodies |
EP2576616A4 (en) | 2010-05-27 | 2014-05-21 | Merck Sharp & Dohme | Method for preparing antibodies having improved properties |
WO2011153243A2 (en) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Anti-angiogenesis therapy for treating gastric cancer |
WO2011153514A2 (en) | 2010-06-03 | 2011-12-08 | Pharmacyclics, Inc. | The use of inhibitors of bruton's tyrosine kinase (btk) |
BR112012029866A2 (en) | 2010-06-03 | 2017-03-07 | Genentech Inc | method for determining the presence of a steap-1 protein |
MX2012014975A (en) | 2010-06-22 | 2013-03-12 | Univ Colorado Regents | Antibodies to the c3d fragment of complement component 3. |
MX2013000301A (en) | 2010-07-09 | 2013-05-09 | Biogen Idec Hemophilia Inc | Chimeric clotting factors. |
EA027835B1 (en) | 2010-07-09 | 2017-09-29 | Круселл Холланд Б.В. | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use thereof |
JP5972871B2 (en) | 2010-07-20 | 2016-08-17 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | Anti-IL-23 heterodimer specific antibody |
WO2012012750A1 (en) | 2010-07-23 | 2012-01-26 | Trustees Of Boston University | ANTI-DEsupR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY |
NZ605928A (en) | 2010-07-29 | 2015-02-27 | Eleven Biotherapeutics Inc | Chimeric il-1 receptor type i agonists and antagonists |
CA2807127C (en) | 2010-08-02 | 2019-02-12 | Leslie S. Johnson | Covalent diabodies and uses thereof |
WO2012019061A2 (en) | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
EP2603526A1 (en) | 2010-08-13 | 2013-06-19 | Medimmune Limited | Monomeric polypeptides comprising variant fc regions and methods of use |
WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
SG10201506782XA (en) | 2010-08-27 | 2015-10-29 | Stem Centrx Inc | Notum protein modulators and methods of use |
CN106620693A (en) | 2010-09-03 | 2017-05-10 | 艾伯维施特姆森特克斯有限责任公司 | Novel modulators and methods of use |
US9228023B2 (en) | 2010-10-01 | 2016-01-05 | Oxford Biotherapeutics Ltd. | Anti-ROR1 antibodies and methods of use for treatment of cancer |
UA112062C2 (en) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | CD33-Binding Agent |
BR112013009083B1 (en) | 2010-10-13 | 2021-08-10 | Janssen Biotech, Inc. | HUMAN ANTIBODIES TO ONCOSTATIN M, ITS MANUFACTURING PROCESS, ANTIGEN-BINDING FRAGMENT, PHARMACEUTICAL COMPOSITION, ISOLATED POLYNUCLEOTIDE, RECOMBINANT HOST CELL STABLELY TRANSFORMED OR TRANSFECTED |
AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
TR201802772T4 (en) | 2010-11-17 | 2018-03-21 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen binding molecule with alternative function for the function of blood coagulation factor VIII. |
RS57502B1 (en) | 2010-11-23 | 2018-10-31 | Glaxo Group Ltd | Antigen binding proteins to oncostatin m (osm) |
EP2643351A1 (en) | 2010-11-24 | 2013-10-02 | Glaxo Group Limited | Multispecific antigen binding proteins targeting hgf |
AR084053A1 (en) | 2010-11-30 | 2013-04-17 | Chugai Pharmaceutical Co Ltd | THERAPEUTIC AGENT THAT INDUCES CYTOTOXICITY |
AU2011337704B2 (en) | 2010-11-30 | 2017-06-15 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
EP2648748A1 (en) | 2010-12-08 | 2013-10-16 | Stem Centrx, Inc. | Novel modulators and methods of use |
JP6147670B2 (en) * | 2010-12-22 | 2017-06-14 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | Modified antibodies with improved half-life |
JOP20210044A1 (en) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | Anti-cd38 antibodies |
WO2012103240A2 (en) | 2011-01-25 | 2012-08-02 | Eleven Biotherapeutics, Inc. | Receptor binding agents |
CA2826453A1 (en) | 2011-02-03 | 2012-08-09 | Alexion Pharmaceuticals, Inc. | Use of an anti-cd200 antibody for prolonging the survival of allografts |
US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
DK2673373T6 (en) | 2011-02-08 | 2021-08-23 | Medimmune Llc | ANTIBODIES SPECIFICALLY BINDING TO STAPHYLOCOCCUS AUREUS ALFA TOXIN, AND METHODS OF USE |
SA112330278B1 (en) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | Novel modulators and methods of use |
MX352889B (en) | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Fcîriib-specific fc antibody. |
PT2691417T (en) | 2011-03-29 | 2018-10-31 | Roche Glycart Ag | Antibody fc variants |
JP2014514313A (en) | 2011-04-20 | 2014-06-19 | ロシュ グリクアート アクチェンゲゼルシャフト | Methods and constructs for pH-dependent passage of the blood brain barrier |
KR20140059168A (en) | 2011-04-21 | 2014-05-15 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | Compositions and methods for the treatment of neuromyelitis optica |
PL2704737T3 (en) | 2011-04-29 | 2018-07-31 | University Of Washington | Therapeutic nuclease compositions and methods |
KR102030531B1 (en) | 2011-05-21 | 2019-10-10 | 마크로제닉스, 인크. | Deimmunized serum-binding domains and their use for extending serum half-life |
EP2714738B1 (en) | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
US9328170B2 (en) | 2011-05-25 | 2016-05-03 | Merck Sharp & Dohme Corp. | Method for preparing Fc containing polypeptides having improved properties |
WO2012170740A2 (en) | 2011-06-07 | 2012-12-13 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
US9561274B2 (en) | 2011-06-07 | 2017-02-07 | University Of Hawaii | Treatment and prevention of cancer with HMGB1 antagonists |
WO2012170969A2 (en) | 2011-06-10 | 2012-12-13 | Biogen Idec Ma Inc. | Pro-coagulant compounds and methods of use thereof |
HUE038509T2 (en) | 2011-06-10 | 2018-10-29 | Medimmune Ltd | Anti-pseudomonas psl binding molecules and uses thereof |
AU2012269720B2 (en) | 2011-06-13 | 2015-01-22 | Csl Limited | Antibodies against G-CSFR and uses thereof |
KR20200044138A (en) | 2011-06-24 | 2020-04-28 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
KR20140068861A (en) * | 2011-06-28 | 2014-06-09 | 인히브릭스 엘엘씨 | Wap domain fusion polypeptides and methods of use thereof |
US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
PE20140756A1 (en) | 2011-06-28 | 2014-07-04 | Oxford Biotherapeutics Ltd | ANTIBODIES THAT JOIN BST1 |
PL2726092T3 (en) * | 2011-06-28 | 2019-11-29 | Inhibrx Lp | Serpin fusion polypeptides and methods of use thereof |
UA117901C2 (en) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Antibody variants and uses thereof |
US9738707B2 (en) | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
WO2013012747A1 (en) | 2011-07-15 | 2013-01-24 | Oncomed Pharmaceuticals, Inc. | Rspo binding agents and uses thereof |
GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
JP6253578B2 (en) | 2011-07-22 | 2017-12-27 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | Inhibitory anti-factor XII / XIIA monoclonal antibodies and their use |
EP2548892A1 (en) | 2011-07-22 | 2013-01-23 | CSL Behring GmbH | Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses |
US20130022551A1 (en) | 2011-07-22 | 2013-01-24 | Trustees Of Boston University | DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS |
CA2842099A1 (en) | 2011-07-27 | 2013-01-31 | Glaxo Group Limited | Antigen binding constructs |
AU2012290379A1 (en) | 2011-07-29 | 2014-02-06 | Eleven Biotherapeutics, Inc. | Purified proteins |
US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
UY34317A (en) | 2011-09-12 | 2013-02-28 | Genzyme Corp | T cell antireceptor antibody (alpha) / ß |
WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
LT3485903T (en) | 2011-09-23 | 2023-02-27 | Mereo Biopharma 5, Inc. | Vegf/dll4 binding agents and uses thereof |
WO2013047752A1 (en) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | Antigen-binding molecule for promoting loss of antigens |
CA2850549C (en) | 2011-09-30 | 2023-03-14 | Teva Pharmaceuticals Australia Pty Ltd. | Antibodies against tl1a and uses thereof |
WO2013047748A1 (en) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
TW201817745A (en) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance |
KR102239138B1 (en) | 2011-09-30 | 2021-04-12 | 추가이 세이야쿠 가부시키가이샤 | Antigen-binding molecule inducing immune response to target antigen |
JP6271251B2 (en) | 2011-10-05 | 2018-01-31 | 中外製薬株式会社 | An antigen-binding molecule that promotes elimination of an antigen containing a sugar chain receptor-binding domain from plasma |
RU2019133467A (en) | 2011-10-11 | 2020-07-06 | МЕДИММЬЮН, ЭлЭлСи | CD40L-SPECIFIC FRAME STRUCTURES ORIGINING FROM TN3, AND METHODS OF APPLICATION |
MX354988B (en) | 2011-10-25 | 2018-03-28 | Prothena Biosciences Ltd | Antibody formulations and methods. |
EP3559049A4 (en) | 2011-10-28 | 2019-12-04 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
ES2697674T3 (en) | 2011-11-01 | 2019-01-25 | Bionomics Inc | Procedures to block the growth of cancer stem cells |
EP2773667A1 (en) | 2011-11-01 | 2014-09-10 | Bionomics, Inc. | Anti-gpr49 antibodies |
AU2012332590B2 (en) | 2011-11-01 | 2016-10-20 | Bionomics, Inc. | Anti-GPR49 antibodies |
JP2014533247A (en) | 2011-11-01 | 2014-12-11 | バイオノミクス インコーポレイテッド | Antibodies and methods of treating cancer |
WO2013063702A1 (en) | 2011-11-04 | 2013-05-10 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
EP2776061B1 (en) | 2011-11-07 | 2019-08-14 | MedImmune, LLC | Multispecific and multivalent binding proteins and uses thereof |
CA3161431A1 (en) | 2011-11-07 | 2013-05-16 | Medimmune Limited | Combination therapies using anti-pseudomonas psl and pcrv binding molecules |
US20140302028A1 (en) * | 2011-11-18 | 2014-10-09 | Merck Sharp & Dohme Corp. | Fc containing polypeptides having increased anti-inflammatory properties and increased fcrn binding |
US9220775B2 (en) | 2011-11-23 | 2015-12-29 | Medimmune Llc | Binding molecules specific for HER3 and uses thereof |
WO2013081143A1 (en) | 2011-11-30 | 2013-06-06 | 中外製薬株式会社 | Drug containing carrier into cell for forming immune complex |
TWI640537B (en) | 2011-12-05 | 2018-11-11 | X 染色體有限公司 | Pdgf receptor beta binding polypeptides |
CA2859667C (en) | 2011-12-20 | 2022-05-24 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
US9688756B2 (en) * | 2011-12-21 | 2017-06-27 | Amgen Inc. | Variant Fc-polypeptides with enhanced binding to the neonatal Fc receptor |
EP2793944A4 (en) | 2011-12-23 | 2015-09-02 | Nicholas B Lydon | Immunoglobulins and variants directed against pathogenic microbes |
US9988439B2 (en) | 2011-12-23 | 2018-06-05 | Nicholas B. Lydon | Immunoglobulins and variants directed against pathogenic microbes |
JP2015502397A (en) | 2011-12-23 | 2015-01-22 | ファイザー・インク | Engineered antibody constant regions for site-specific conjugation, and methods and uses therefor |
KR102041412B1 (en) * | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | Derivatives of Immunglobulin Fc fragment |
CA2896951A1 (en) | 2012-01-10 | 2013-07-18 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
BR112014017165B1 (en) | 2012-01-12 | 2023-05-02 | Bioverativ Therapeutics Inc | CHIMERIC PROTEIN COMPRISING A FACTOR VIII PROTEIN, PHARMACEUTICAL COMPOSITION, AND USES THEREOF |
EP2623110A1 (en) | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
EP2813568A4 (en) * | 2012-02-09 | 2016-04-06 | Chugai Pharmaceutical Co Ltd | Modified fc region of antibody |
JP6256882B2 (en) | 2012-02-15 | 2018-01-10 | アムニクス オペレーティング インコーポレイテッド | Factor VIII composition, and method of making and use of the composition |
JP6383666B2 (en) | 2012-02-15 | 2018-08-29 | バイオベラティブ セラピューティクス インコーポレイテッド | Recombinant factor VIII protein |
DK2817338T3 (en) | 2012-02-24 | 2017-10-23 | Abbvie Stemcentrx Llc | DLL3 modulators and methods of use |
JP6138108B2 (en) | 2012-02-24 | 2017-05-31 | 中外製薬株式会社 | Antigen-binding molecule that promotes disappearance of antigen via FcγRIIB |
TWI605060B (en) | 2012-03-28 | 2017-11-11 | 賽諾菲公司 | Antibodies to bradykinin b1 receptor ligands |
US10385395B2 (en) | 2012-04-11 | 2019-08-20 | The Regents Of The University Of California | Diagnostic tools for response to 6-thiopurine therapy |
US9212227B2 (en) | 2012-04-30 | 2015-12-15 | Janssen Biotech, Inc. | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
WO2013165690A1 (en) * | 2012-04-30 | 2013-11-07 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
CA2872856A1 (en) | 2012-05-07 | 2013-11-14 | Sanofi | Methods for preventing biofilm formation |
US20130336973A1 (en) | 2012-05-10 | 2013-12-19 | Zymeworks Inc. | Heteromultimer Constructs of Immunoglobulin Heavy Chains with Mutations in the Fc Domain |
GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
WO2013175276A1 (en) | 2012-05-23 | 2013-11-28 | Argen-X B.V | Il-6 binding molecules |
DK2857420T3 (en) | 2012-05-30 | 2020-11-23 | Chugai Pharmaceutical Co Ltd | TARGET TISSUE SPECIFIC ANTIGIN BINDING MOLECULE |
US20150353630A1 (en) | 2012-05-30 | 2015-12-10 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for eliminating aggregated antigens |
CA2875980A1 (en) | 2012-06-06 | 2013-12-12 | Oncomed Pharmaceuticals, Inc. | Binding agents that modulate the hippo pathway and uses thereof |
AU2013270683A1 (en) | 2012-06-08 | 2014-12-11 | Biogen Ma Inc. | Chimeric clotting factors |
JP2015521589A (en) | 2012-06-08 | 2015-07-30 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Procoagulant compounds |
WO2014004586A1 (en) | 2012-06-25 | 2014-01-03 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
EP2870250B2 (en) | 2012-07-06 | 2022-06-29 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor viii polypeptides and uses thereof |
US11180572B2 (en) | 2012-07-06 | 2021-11-23 | Genmab B.V. | Dimeric protein with triple mutations |
EP3632462A1 (en) | 2012-07-06 | 2020-04-08 | Genmab B.V. | Dimeric protein with triple mutations |
SG10201913893XA (en) | 2012-07-11 | 2020-03-30 | Bioverativ Therapeutics Inc | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
HUE056217T2 (en) | 2012-07-13 | 2022-02-28 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
JP6575950B2 (en) | 2012-07-24 | 2019-09-18 | ファーマサイクリックス エルエルシー | Mutations with resistance to Bruton tyrosine kinase (Btk) inhibitors |
US9334332B2 (en) | 2012-07-25 | 2016-05-10 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies |
EP2888279A1 (en) | 2012-08-22 | 2015-07-01 | Glaxo Group Limited | Anti lrp6 antibodies |
SG10201709559PA (en) | 2012-08-24 | 2017-12-28 | Chugai Pharmaceutical Co Ltd | Fcγriib-specific fc region variant |
EP3597747B1 (en) | 2012-08-24 | 2023-03-15 | Chugai Seiyaku Kabushiki Kaisha | Mouse fcgammarii-specific fc antibody |
PT3366705T (en) | 2012-09-12 | 2023-07-19 | Genzyme Corp | Fc containing polypeptides with altered glycosylation and reduced effector function |
US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
AR093788A1 (en) | 2012-12-04 | 2015-06-24 | Oncomed Pharm Inc | IMMUNOTHERAPY WITH LINK AGENTS |
WO2014100439A2 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
JP6359031B2 (en) | 2012-12-21 | 2018-07-18 | メディミューン,エルエルシー | Anti-H7CR antibody |
EP2943506B1 (en) | 2013-01-10 | 2024-03-13 | Genmab B.V. | Human igg1 fc region variants and uses thereof |
RU2015130100A (en) | 2013-01-24 | 2017-03-03 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | TNF-alpha antigen binding proteins |
MX362105B (en) | 2013-01-25 | 2019-01-04 | Shire Human Genetic Therapies | Follistatin in treating duchenne muscular dystrophy. |
CA2899960C (en) | 2013-02-01 | 2022-05-03 | Transbio Ltd | Anti-cd83 antibodies and use thereof |
CN105073195A (en) | 2013-02-04 | 2015-11-18 | 昂科梅德制药有限公司 | Methods and monitoring of treatment with a Wnt pathway inhibitor |
US9340618B2 (en) | 2013-02-07 | 2016-05-17 | Csl Limited | IL-11R binding proteins |
EP3889173B1 (en) | 2013-02-15 | 2023-07-05 | Bioverativ Therapeutics Inc. | Optimized factor viii gene |
MX2015010682A (en) | 2013-02-22 | 2016-05-31 | Stemcentrx Inc | Novel antibody conjugates and uses thereof. |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
CA2901225C (en) | 2013-03-08 | 2023-09-19 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
IL275376B2 (en) | 2013-03-11 | 2024-01-01 | Genzyme Corp | Hyperglycosylated binding polypeptides |
JP6450364B2 (en) | 2013-03-13 | 2019-01-09 | セセン バイオ, インコーポレイテッド | Chimeric cytokine formulations for ocular delivery |
US20140271641A1 (en) | 2013-03-14 | 2014-09-18 | University Of Guelph | Thrombospondin-1 polypeptides and methods of using same |
PL2968520T3 (en) | 2013-03-14 | 2022-01-03 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor |
RU2015144033A (en) | 2013-03-15 | 2017-04-26 | Эббви Байотекнолоджи Лтд. | ANTIBODIES AGAINST CD25 AND THEIR APPLICATION |
DK3460054T3 (en) | 2013-03-15 | 2021-01-18 | Atyr Pharma Inc | Histidyl-tRNA-synthetase-Fc conjugates |
US9260527B2 (en) | 2013-03-15 | 2016-02-16 | Sdix, Llc | Anti-human CXCR4 antibodies and methods of making same |
JP2016515524A (en) | 2013-03-15 | 2016-05-30 | アッヴィ バイオテクノロジー リミテッド | Anti-CD25 antibodies and their use |
AU2014230741B2 (en) | 2013-03-15 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Anti-LAG-3 binding proteins |
EA201890895A1 (en) | 2013-03-15 | 2019-02-28 | Зинджения, Инк. | MULTIVALENT AND MONOVALENT MULTIS-SPECIFIC COMPLEXES AND THEIR APPLICATION |
CA2899089C (en) | 2013-03-15 | 2021-10-26 | Biogen Ma Inc. | Factor ix polypeptide formulations |
US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
CN105143257B (en) | 2013-03-15 | 2020-10-27 | 艾伯维生物医疗股份有限公司 | FC variants |
EP3424952A1 (en) | 2013-03-15 | 2019-01-09 | Amgen, Inc | Heterodimeric bispecific antibodies |
US11267868B2 (en) | 2013-04-02 | 2022-03-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
EP2992013B1 (en) | 2013-04-29 | 2019-12-04 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
EP2999716A2 (en) | 2013-05-20 | 2016-03-30 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies and methods of use |
US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
EP3043813B1 (en) | 2013-08-08 | 2021-01-13 | Bioverativ Therapeutics Inc. | Purification of chimeric fviii molecules |
US11384149B2 (en) | 2013-08-09 | 2022-07-12 | Macrogenics, Inc. | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof |
UA116479C2 (en) | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof |
SG10201710013RA (en) | 2013-08-13 | 2018-01-30 | Sanofi Sa | Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof |
TW201722994A (en) | 2013-08-13 | 2017-07-01 | 賽諾菲公司 | Antibodies to Plasminogen Activator Inhibitor-1 (PAI-1) and uses thereof |
US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
EP2840091A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof |
EP2839842A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
EP3338793A1 (en) | 2013-08-28 | 2018-06-27 | AbbVie Stemcentrx LLC | Novel sez6 modulators and methods of use |
EP3892294A1 (en) | 2013-08-28 | 2021-10-13 | AbbVie Stemcentrx LLC | Site-specific antibody conjugation methods and compositions |
WO2015035044A2 (en) | 2013-09-04 | 2015-03-12 | Abbvie Biotherapeutics Inc. | Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY |
JP6623353B2 (en) | 2013-09-13 | 2019-12-25 | ベイジーン スウィッツァーランド ゲーエムベーハー | Anti-PD-1 antibodies and their use for therapy and diagnosis |
EP3733710A1 (en) | 2013-09-25 | 2020-11-04 | Amgen, Inc | Hetrodimeric v-c-fc-v-c antibody |
EP3048899B1 (en) | 2013-09-25 | 2021-09-08 | Bioverativ Therapeutics Inc. | On-column viral inactivation methods |
BR112016006197B1 (en) | 2013-09-27 | 2023-04-11 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR PRODUCING A BISPECIFIC POLYPEPTIDE ANTIBODY |
WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
KR102501920B1 (en) | 2013-10-02 | 2023-02-20 | 메디뮨 엘엘씨 | Neutralizing anti-influenza a antibodies and uses thereof |
PT3055331T (en) | 2013-10-11 | 2021-04-05 | Oxford Bio Therapeutics Ltd | Conjugated antibodies against ly75 for the treatment of cancer |
US10988745B2 (en) | 2013-10-31 | 2021-04-27 | Resolve Therapeutics, Llc | Therapeutic nuclease-albumin fusions and methods |
RU2016122041A (en) | 2013-11-06 | 2017-12-11 | ЭББВИ СТЕМСЕНТРКС ЭлЭлСи | NEW ANTI-CLAUDIN ANTIBODIES AND WAYS OF THEIR APPLICATION |
EP3065769A4 (en) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Procoagulant fusion compound |
GB201320066D0 (en) | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
EP3074039A4 (en) * | 2013-11-26 | 2017-10-11 | The Brigham and Women's Hospital, Inc. | Compositions and methods for modulating an immune response |
TW201610168A (en) | 2013-12-02 | 2016-03-16 | 安可美德藥物股份有限公司 | Identification of predictive biomarkers associated with Wnt pathway inhibitors |
SG11201604495PA (en) | 2013-12-04 | 2016-07-28 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules |
CN113861293A (en) | 2013-12-09 | 2021-12-31 | 爱乐科斯公司 | anti-Siglec-8 antibodies and methods of use thereof |
EP2883883A1 (en) | 2013-12-16 | 2015-06-17 | Cardio3 Biosciences S.A. | Therapeutic targets and agents useful in treating ischemia reperfusion injury |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
CN106103476B (en) | 2013-12-24 | 2020-11-27 | 阿尔金克斯有限公司 | FcRn antagonists and methods of use |
RS63583B1 (en) | 2014-01-10 | 2022-10-31 | Bioverativ Therapeutics Inc | Factor viii chimeric proteins and uses thereof |
JP2017506640A (en) | 2014-02-14 | 2017-03-09 | セントローズ, エルエルシー | Extracellular targeted drug conjugates |
JP6825909B2 (en) | 2014-02-28 | 2021-02-03 | アラコス インコーポレイテッド | Methods and Compositions for Treating SIGLEC-8 Related Diseases |
NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
MA39746A (en) | 2014-03-14 | 2021-04-28 | Hoffmann La Roche | HETEROLOGICAL POLYPEPTIDE SECRETION COMPOSITIONS AND ASSOCIATED PROCESSES |
US9738702B2 (en) * | 2014-03-14 | 2017-08-22 | Janssen Biotech, Inc. | Antibodies with improved half-life in ferrets |
SG10201808158UA (en) | 2014-03-19 | 2018-10-30 | Genzyme Corp | Site-specific glycoengineering of targeting moieties |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
CA2943242A1 (en) | 2014-03-21 | 2015-09-24 | X-Body, Inc. | Bi-specific antigen-binding polypeptides |
CN106536556B (en) | 2014-04-04 | 2020-02-07 | 生态学有限公司 | Humanized antibodies that bind LGR5 |
KR102546611B1 (en) | 2014-04-08 | 2023-06-22 | 보스턴 파마슈티칼즈, 아이엔씨. | Binding molecules specific for il-21 and uses of thereof |
UA119352C2 (en) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof |
CN106413750B (en) * | 2014-05-16 | 2022-04-29 | 免疫医疗有限责任公司 | Molecules with altered neonatal Fc receptor binding with enhanced therapeutic and diagnostic properties |
MA47849A (en) | 2014-05-28 | 2020-01-29 | Agenus Inc | ANTI-GITR ANTIBODIES AND THEIR METHODS OF USE |
JP6675329B2 (en) * | 2014-06-12 | 2020-04-01 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Methods for selecting antibodies with altered FcRn interactions |
US10562946B2 (en) | 2014-06-20 | 2020-02-18 | Genentech, Inc. | Chagasin-based scaffold compositions, methods, and uses |
US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
JP6526189B2 (en) | 2014-07-03 | 2019-06-05 | ベイジーン リミテッド | Anti-PD-L1 antibodies and their use for therapy and diagnosis |
CN113563462A (en) | 2014-07-15 | 2021-10-29 | 免疫医疗有限责任公司 | Neutralizing anti-influenza b antibodies and uses thereof |
BR112017001385B1 (en) | 2014-07-22 | 2023-12-05 | Cb Therapeutics, Inc. | ISOLATED ANTIBODY OR FRAGMENT THEREOF THAT BINDS PD-1, USE OF IT, COMPOSITION, ISOLATED POLYNUCLEOTIDE AND EXPRESSION VECTOR |
KR102476226B1 (en) | 2014-08-05 | 2022-12-12 | 아폴로믹스 인코포레이티드 | Anti-pd-l1 antibodies |
WO2016025331A1 (en) | 2014-08-11 | 2016-02-18 | University Of Massachusetts | Anti-ospa antibodies and methods of use |
AR101753A1 (en) | 2014-09-03 | 2017-01-11 | Boehringer Ingelheim Int | COMPOUND OF OBJECTIVE TO IL-23A AND TNF-A AND USE OF THE SAME |
TW201617368A (en) | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | Novel anti-MFI2 antibodies and methods of use |
US20170247476A1 (en) | 2014-09-25 | 2017-08-31 | Amgen Inc. | Protease-activatable bispecific proteins |
AP2017009826A0 (en) | 2014-09-26 | 2017-03-31 | Bayer Pharma AG | Stabilized adrenomedullin derivatives and use thereof |
MA40764A (en) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | THERAPEUTIC AGENT INDUCING CYTOTOXICITY |
CN107108721B (en) | 2014-09-29 | 2021-09-07 | 杜克大学 | Bispecific molecules comprising an HIV-1 envelope targeting arm |
CN106715473B (en) * | 2014-10-01 | 2021-11-23 | 免疫医疗有限公司 | Antibodies to ticagrelor and methods of use thereof |
CA2964123C (en) | 2014-10-09 | 2023-09-05 | Genzyme Corporation | Glycoengineered antibody drug conjugates |
NZ730563A (en) | 2014-10-14 | 2019-05-31 | Halozyme Inc | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
US10870704B2 (en) | 2014-10-23 | 2020-12-22 | Kira Biotech Pty Limited | CD83 binding proteins and uses thereof |
AU2015337858B2 (en) | 2014-10-29 | 2020-09-24 | Teva Pharmaceuticals Australia Pty Ltd. | Interferon alpha2b variants |
US20160130324A1 (en) * | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
CA2961439A1 (en) | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Anti-fgfr2/3 antibodies and methods using same |
AR102522A1 (en) * | 2014-11-06 | 2017-03-08 | Hoffmann La Roche | FC REGION VARIATIONS WITH MODIFIED PROPERTIES OF UNION TO FCRN AND PROTEIN A |
AU2015345202B2 (en) | 2014-11-10 | 2021-05-13 | Medimmune Limited | Binding molecules specific for CD73 and uses thereof |
JP6847037B2 (en) | 2014-11-11 | 2021-03-24 | メディミューン リミテッド | Concomitant therapeutic agents containing anti-CD73 antibody and A2A receptor inhibitor and their use |
US10508151B2 (en) | 2014-11-19 | 2019-12-17 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
US11008403B2 (en) | 2014-11-19 | 2021-05-18 | Genentech, Inc. | Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use |
RS60631B1 (en) | 2014-11-21 | 2020-09-30 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
EP3221346B1 (en) | 2014-11-21 | 2020-09-02 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
US9382321B2 (en) | 2014-11-26 | 2016-07-05 | Adventis Health System/Sunbelt, Inc. | Effector-deficient anti-CD32A antibodies |
RU2017120039A (en) | 2014-12-10 | 2019-01-10 | Дженентек, Инк. | ANTIBODIES TO HEMATOENCEPHALIC BARRIER RECEPTORS AND METHODS OF APPLICATION |
PE20221834A1 (en) | 2014-12-19 | 2022-11-29 | Chugai Pharmaceutical Co Ltd | ANTIMYOSTATIN ANTIBODIES |
RU2746356C2 (en) | 2014-12-19 | 2021-04-12 | Чугаи Сейяку Кабусики Кайся | C5 antibodies and their application methods |
WO2016094962A1 (en) | 2014-12-19 | 2016-06-23 | Monash University | Il-21 antibodies |
EP3789039A1 (en) | 2014-12-22 | 2021-03-10 | The Rockefeller University | Anti-mertk agonistic antibodies and uses thereof |
TWI708786B (en) | 2014-12-23 | 2020-11-01 | 美商必治妥美雅史谷比公司 | Antibodies to tigit |
CA2973978A1 (en) | 2015-01-14 | 2016-07-21 | The Brigham And Women's Hospital, Inc. | Treatment of cancer with anti-lap monoclonal antibodies |
EP3250588A1 (en) | 2015-01-29 | 2017-12-06 | Board of Trustees of Michigan State University | Cryptic polypeptides and uses thereof |
KR20170110129A (en) | 2015-02-05 | 2017-10-10 | 추가이 세이야쿠 가부시키가이샤 | Antibodies comprising ionic concentration dependent antigen binding domains, Fc region variants, antibodies that bind to IL-8, and their use |
WO2016131893A1 (en) | 2015-02-18 | 2016-08-25 | Medimmune Limited | Incretin fusion polypeptides |
TWI805046B (en) | 2015-02-27 | 2023-06-11 | 日商中外製藥股份有限公司 | Use of IL-6 receptor antibody for preparing pharmaceutical composition |
JP2018509413A (en) | 2015-03-09 | 2018-04-05 | アルゲン−エックス ビーブイビーエー | Methods for reducing serum levels of Fc-containing agents using FcRn antagonists |
EP3277717B1 (en) | 2015-03-31 | 2020-11-18 | Medimmune Limited | A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same |
FR3034420A1 (en) | 2015-03-31 | 2016-10-07 | Lab Francais Du Fractionnement | ANTI-CD303 MONOCLONAL ANTIBODIES |
EP3279216A4 (en) | 2015-04-01 | 2019-06-19 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
CA2987410A1 (en) | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Antibodies against ox40 and uses thereof |
KR102141446B1 (en) | 2015-06-04 | 2020-08-06 | 오스페달레 산 라파엘 에스.알.엘. | IFP3 and its use |
AU2016272045B2 (en) | 2015-06-04 | 2018-04-19 | Ospedale San Raffaele Srl | Inhibitor of IGFBP3/TMEM219 axis and diabetes |
CN107849124B (en) | 2015-06-05 | 2021-09-24 | 基因泰克公司 | anti-TAU antibodies and methods of use |
TWI773646B (en) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | Lag-3-binding molecules and methods of use thereof |
JP6846362B2 (en) | 2015-06-17 | 2021-03-24 | アラコス インコーポレイテッド | Methods and Compositions for Treating Fibrous Diseases |
AU2016285920A1 (en) | 2015-06-29 | 2018-02-01 | Bristol-Myers Squibb Company | Antibodies to CD40 with enhanced agonist activity |
TW202144411A (en) | 2015-07-23 | 2021-12-01 | 德商包林格因蓋爾漢國際股份有限公司 | Compound targeting il-23a and b-cell activating factor (baff) and uses thereof |
KR20180034588A (en) | 2015-07-30 | 2018-04-04 | 마크로제닉스, 인크. | PD-1-binding molecules and methods for their use |
JP2018529756A (en) | 2015-07-31 | 2018-10-11 | メディミューン リミテッド | Methods for treating hepcidin-mediated disorders |
BR112018002150A2 (en) | 2015-08-03 | 2018-09-18 | Bioverativ Therapeutics Inc | factor ix fusion proteins and methods of manufacturing and using them |
EA201890630A1 (en) | 2015-09-01 | 2018-10-31 | Эйдженус Инк. | ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION |
EP3798234A1 (en) | 2015-09-02 | 2021-03-31 | Immutep S.A.S. | Anti-lag-3 agonistic antibodies |
WO2017046746A1 (en) | 2015-09-15 | 2017-03-23 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist |
TWI799366B (en) | 2015-09-15 | 2023-04-21 | 美商建南德克公司 | Cystine knot scaffold platform |
TWI703158B (en) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | Antibodies that specifically bind to tl1a |
EP3353204B1 (en) | 2015-09-23 | 2023-10-18 | Mereo BioPharma 5, Inc. | Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer |
KR20180051651A (en) | 2015-10-01 | 2018-05-16 | 히트 바이오로직스, 인코퍼레이티드 | Compositions and methods for adjacent I and II extracellular domains as heterologous chimeric proteins |
WO2017062619A2 (en) | 2015-10-08 | 2017-04-13 | Macrogenics, Inc. | Combination therapy for the treatment of cancer |
MX2018004474A (en) | 2015-10-12 | 2018-11-09 | Aprogen Kic Inc | Anti-cd43 antibody and use thereof for cancer treatment. |
US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
RU2710194C9 (en) | 2015-11-10 | 2020-09-14 | МЕДИММЬЮН, ЭлЭлСи | Binding molecules specific for asct2, and their use |
WO2017095808A1 (en) | 2015-11-30 | 2017-06-08 | Abbvie Inc. | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE |
JP2019500327A (en) | 2015-11-30 | 2019-01-10 | アッヴィ・インコーポレイテッド | Anti-huLRRC15 antibody drug conjugate and method of use thereof |
CN108883173B (en) | 2015-12-02 | 2022-09-06 | 阿吉纳斯公司 | Antibodies and methods of use thereof |
CR20180318A (en) | 2015-12-14 | 2018-09-19 | Macrogenics Inc | BISPECIFIC MOLECULES THAT HAVE IMMUNORREACTIVITY WITH PD-1 AND CTLA-4, AND METHODS OF USE OF THE SAME |
US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
WO2017115773A1 (en) | 2015-12-28 | 2017-07-06 | 中外製薬株式会社 | Method for promoting efficiency of purification of fc region-containing polypeptide |
CN107406511B (en) | 2015-12-31 | 2021-01-19 | 江苏恒瑞医药股份有限公司 | PCSK9 antibody, antigen-binding fragment thereof and medical application thereof |
EP3401336A4 (en) | 2016-01-05 | 2020-01-22 | Jiangsu Hengrui Medicine Co., Ltd. | Pcsk9 antibody, antigen-binding fragment thereof, and medical uses thereof |
DK3411478T3 (en) | 2016-02-01 | 2022-09-12 | Bioverativ Therapeutics Inc | OPTIMIZED FACTOR VIII GENES |
UY37127A (en) | 2016-02-17 | 2017-08-31 | Macrogenics Inc | MOLECULES OF UNION TO ROR1, AND METHODS OF USE OF THE SAME |
SG11201807677YA (en) | 2016-03-04 | 2018-10-30 | Univ Rockefeller | Antibodies to cd40 with enhanced agonist activity |
EA201891983A8 (en) | 2016-03-04 | 2020-05-28 | Бристол-Майерс Сквибб Компани | COMBINED THERAPY BY ANTIBODIES TO CD73 |
MA43588A (en) | 2016-03-04 | 2021-06-02 | Takeda Pharmaceuticals Co | RECOMBINANT FOLLISTATINE-FC FUSION PROTEINS AND THEIR USE IN THE TREATMENT OF DUCHENNE MUSCLE DYSTROPHY |
TW202342540A (en) | 2016-03-14 | 2023-11-01 | 日商中外製藥股份有限公司 | Cell injury inducing therapeutic drug for use in cancer therapy |
US11066464B2 (en) | 2016-03-21 | 2021-07-20 | Kymab Limited | Anti-malarial antibodies that bind circumsporozoite protein |
US10745487B2 (en) | 2016-03-22 | 2020-08-18 | Bionomics Limited | Method of treating cancer by administering an anti-LGR5 monoclonal antibody |
BR112018070357A2 (en) | 2016-04-04 | 2019-01-29 | Bioverativ Usa Inc | anti-complement antibodies against factor bb and their uses |
MA45473A (en) | 2016-04-04 | 2019-02-13 | Shire Human Genetic Therapies | CONJUGATE C1 ESTERASE INHIBITOR AND ITS USES |
MY198114A (en) | 2016-04-15 | 2023-08-04 | Macrogenics Inc | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof |
EP3454864A4 (en) | 2016-04-21 | 2021-01-13 | Abbvie Stemcentrx LLC | Novel anti-bmpr1b antibodies and methods of use |
MX2018014387A (en) | 2016-05-27 | 2019-03-14 | Agenus Inc | Anti-tim-3 antibodies and methods of use thereof. |
EP3468997B1 (en) | 2016-06-08 | 2023-09-13 | Xencor, Inc. | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b |
SI3478713T1 (en) | 2016-06-30 | 2022-06-30 | Prothena Biosciences Limited | Compositions for treating amyloidosis |
MA45554A (en) | 2016-07-01 | 2019-05-08 | Resolve Therapeutics Llc | OPTIMIZED BINUCLEASE FUSIONS. |
CN109475536B (en) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | Combination of a PD-l antagonist and a RAF inhibitor for the treatment of cancer |
KR20190039937A (en) | 2016-07-08 | 2019-04-16 | 스태튼 바이오테크놀로지 비.브이. | Anti-ApoC3 antibodies and methods of use thereof |
WO2018013917A1 (en) | 2016-07-15 | 2018-01-18 | Takeda Pharmaceutical Company Limited | Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies |
WO2018014067A1 (en) | 2016-07-19 | 2018-01-25 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd47 combination therapy |
US11858980B2 (en) | 2016-08-02 | 2024-01-02 | Visterra, Inc. | Engineered polypeptides and uses thereof |
CN109689090B (en) | 2016-08-05 | 2023-12-26 | 免疫医疗有限责任公司 | anti-O2 antibodies and uses thereof |
CN116251182A (en) | 2016-08-05 | 2023-06-13 | 中外制药株式会社 | Compositions for preventing or treating IL-8 related diseases |
WO2018035107A2 (en) * | 2016-08-15 | 2018-02-22 | Board Of Regents, The University Of Texas System | Stabilized pertussis antibodies with extended half-life |
US10538579B2 (en) | 2016-08-15 | 2020-01-21 | Board Of Regents, The University Of Texas System | Bispecific pertussis antibodies |
AU2017313085A1 (en) | 2016-08-19 | 2019-03-14 | Beigene Switzerland Gmbh | Use of a combination comprising a Btk inhibitor for treating cancers |
JP2019534858A (en) | 2016-09-09 | 2019-12-05 | ジェネンテック, インコーポレイテッド | Selective peptide inhibitor of FRIZZLED |
EP3512883A1 (en) | 2016-09-13 | 2019-07-24 | Humanigen, Inc. | Epha3 antibodies for the treatment of pulmonary fibrosis |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
TW202246349A (en) | 2016-10-11 | 2022-12-01 | 美商艾吉納斯公司 | Anti-lag-3 antibodies and methods of use thereof |
SG11201903063UA (en) | 2016-10-19 | 2019-05-30 | Medimmune Llc | Anti-o1 antibodies and uses thereof |
US11286295B2 (en) | 2016-10-20 | 2022-03-29 | Sanofi | Anti-CHIKV monoclonal antibodies directed against the E2 structural protein |
EP3529270A2 (en) | 2016-10-21 | 2019-08-28 | Adimab, LLC | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
JP7265984B2 (en) | 2016-10-21 | 2023-04-27 | アディマブ, エルエルシー | Anti-respiratory syncytial virus antibodies and methods of their production and use |
IL303833A (en) | 2016-10-21 | 2023-08-01 | Adimab Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
TWI788307B (en) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion |
CA3041340A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
BR112019011198A2 (en) | 2016-12-02 | 2019-12-17 | Bioverativ Therapeutics Inc | methods of inducing immune tolerance to coagulation factors |
IL266972B2 (en) | 2016-12-02 | 2024-04-01 | Bioverativ Therapeutics Inc | Methods of treating hemophilic arthropathy using chimeric clotting factors |
WO2018104893A1 (en) | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life |
CR20230163A (en) | 2016-12-07 | 2023-07-06 | Genentech Inc | Anti-tau antibodies and methods of use |
AU2017373884A1 (en) | 2016-12-07 | 2019-05-30 | Ac Immune Sa | Anti-tau antibodies and methods of their use |
MX2019006340A (en) | 2016-12-07 | 2019-11-07 | Agenus Inc | Anti-ctla-4 antibodies and methods of use thereof. |
CA3046082A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Antibodies and methods of use thereof |
US11267883B2 (en) | 2016-12-21 | 2022-03-08 | Cephalon, Inc. | Antibodies that specifically bind to human IL-15 and uses thereof |
EP3558368A4 (en) | 2016-12-23 | 2020-12-30 | MacroGenics, Inc. | Adam9-binding molecules, and methods of use thereof |
DK3558391T3 (en) | 2016-12-23 | 2022-05-09 | Immunogen Inc | IMMUNE CONJUGATES WITH ADAM9 AS OBJECTIVES AND PROCEDURES FOR USING IT |
TW201825515A (en) | 2017-01-04 | 2018-07-16 | 美商伊繆諾金公司 | Met antibodies and immunoconjugates and uses thereof |
US20200121719A1 (en) | 2017-01-06 | 2020-04-23 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists |
US11357841B2 (en) | 2017-01-06 | 2022-06-14 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
WO2018140427A1 (en) | 2017-01-25 | 2018-08-02 | Molecular Templates, Inc. | Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes |
CN110225924B (en) | 2017-01-25 | 2024-04-02 | 免疫医疗有限公司 | Relaxin fusion polypeptides and uses thereof |
CN110461847B (en) | 2017-01-25 | 2022-06-07 | 百济神州有限公司 | Crystalline forms of (S) -7- (1- (but-2-alkynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4,5,6, 7-tetrahydropyrazolo [1,5-a ] pyrimidine-3-carboxamide, preparation and use thereof |
EP3576790A4 (en) | 2017-02-01 | 2020-12-23 | Yale University | Treatment of diuretic resistance |
JP7304288B2 (en) | 2017-02-17 | 2023-07-06 | サノフイ | Multispecific binding molecules with specificity for dystroglycan and laminin-2 |
AU2018221731C1 (en) | 2017-02-17 | 2021-11-18 | Denali Therapeutics Inc. | Engineered transferrin receptor binding polypeptides |
US10626169B2 (en) | 2017-02-17 | 2020-04-21 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
US11459394B2 (en) | 2017-02-24 | 2022-10-04 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
AU2018224852A1 (en) | 2017-02-27 | 2019-07-11 | Shattuck Labs, Inc. | VSIG8-based chimeric proteins |
GB201703876D0 (en) | 2017-03-10 | 2017-04-26 | Berlin-Chemie Ag | Pharmaceutical combinations |
KR20190129925A (en) | 2017-03-16 | 2019-11-20 | 메디뮨 리미티드 | Anti-PAR2 Antibodies and Their Uses |
UY37651A (en) | 2017-03-31 | 2018-10-31 | Swedish Orphan Biovitrum Ab Publ | IL-1R-I UNION POLYPEPTIDE |
TWI788340B (en) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | Anti-icos agonist antibodies and uses thereof |
BR112019017241A2 (en) | 2017-04-13 | 2020-04-14 | Agenus Inc | anti-cd137 antibodies and methods of using them |
WO2018192974A1 (en) | 2017-04-18 | 2018-10-25 | Université Libre de Bruxelles | Biomarkers and targets for proliferative diseases |
JP2020517638A (en) | 2017-04-20 | 2020-06-18 | エータイアー ファーマ, インコーポレイテッド | Compositions and methods for treating lung inflammation |
CN110506056A (en) | 2017-04-21 | 2019-11-26 | 斯塔滕生物技术有限公司 | Anti- APOC3 antibody and its application method |
EP3618863B1 (en) | 2017-05-01 | 2023-07-26 | Agenus Inc. | Anti-tigit antibodies and methods of use thereof |
JP7185884B2 (en) | 2017-05-02 | 2022-12-08 | 国立研究開発法人国立精神・神経医療研究センター | METHOD FOR PREDICTING AND DETERMINING THERAPEUTIC EFFECT OF IL-6 AND NEUTROPHIL-RELATED DISEASE |
MX2019013137A (en) | 2017-05-05 | 2020-07-14 | Allakos Inc | Methods and compositions for treating allergic ocular diseases. |
US20200224161A1 (en) | 2017-05-10 | 2020-07-16 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
MX2019013523A (en) | 2017-05-12 | 2020-07-14 | Takeda Pharmaceuticals Co | Recombinant follistatin-fc fusion proteins and use in treating duchenne muscular dystrophy. |
JOP20190271A1 (en) | 2017-05-24 | 2019-11-21 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use for immune related disorders |
KR20220167342A (en) | 2017-05-25 | 2022-12-20 | 브리스톨-마이어스 스큅 컴퍼니 | Antibodies comprising modified heavy constant regions |
GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
CA3066518A1 (en) | 2017-06-26 | 2019-01-03 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
US11365241B2 (en) | 2017-07-27 | 2022-06-21 | Alexion Pharmaceuticals, Inc. | High concentration anti-C5 antibody formulations |
CN111247251A (en) | 2017-08-09 | 2020-06-05 | 比奥维拉迪维治疗股份有限公司 | Nucleic acid molecules and uses thereof |
SG11202001311VA (en) | 2017-08-22 | 2020-03-30 | Sanabio Llc | Soluble interferon receptors and uses thereof |
WO2019040780A1 (en) | 2017-08-25 | 2019-02-28 | Five Prime Therapeutics Inc. | B7-h4 antibodies and methods of use thereof |
CA3080103A1 (en) | 2017-10-31 | 2019-05-09 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
US10538583B2 (en) | 2017-10-31 | 2020-01-21 | Staten Biotechnology B.V. | Anti-APOC3 antibodies and compositions thereof |
CA3083118A1 (en) | 2017-11-22 | 2019-05-31 | Iovance Biotherapeutics, Inc. | Expansion of peripheral blood lymphocytes (pbls) from peripheral blood |
WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
PL3717011T3 (en) | 2017-11-29 | 2023-03-27 | Csl Limited | Method of treating or preventing ischemia-reperfusion injury |
MX2020005981A (en) | 2017-12-08 | 2020-08-24 | Argenx Bvba | Use of fcrn antagonists for treatment of generalized myasthenia gravis. |
RU2020122822A (en) | 2017-12-12 | 2022-01-13 | Макродженикс, Инк. | BISPECIFIC CD16 BINDING MOLECULES AND THEIR USE IN THE TREATMENT OF DISEASES |
JP2021508104A (en) | 2017-12-15 | 2021-02-25 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Systems and methods for determining beneficial administration of tumor-infiltrating lymphocytes and their use, as well as beneficial administration of tumor-infiltrating lymphocytes and their use. |
EP3498293A1 (en) | 2017-12-15 | 2019-06-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Treatment of monogenic diseases with an anti-cd45rc antibody |
US11802154B2 (en) | 2017-12-20 | 2023-10-31 | Alexion Pharmaceuticals, Inc. | Humanized anti-CD200 antibodies and uses thereof |
EP3732198A1 (en) | 2017-12-27 | 2020-11-04 | Bristol-Myers Squibb Company | Anti-cd40 antibodies and uses thereof |
FR3076294B1 (en) | 2017-12-29 | 2022-01-28 | Lab Francais Du Fractionnement | METHOD FOR PURIFYING ANTIBODIES FROM RAW MILK |
BR112020013519A2 (en) | 2018-01-05 | 2020-12-01 | Corvidia Therapeutics, Inc | method for treating an inflammation. |
AU2019207600A1 (en) | 2018-01-09 | 2020-07-09 | Theriva Biologics, Inc. | Alkaline phosphatase agents for treatment of neurodevelopmental disorders |
WO2019140410A1 (en) | 2018-01-12 | 2019-07-18 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-cd38 antibodies |
BR112020015228A2 (en) | 2018-02-01 | 2020-12-29 | Bioverativ Therapeutics Inc. | USE OF LENTIVIRAL VECTORS THAT EXPRESS FACTOR VIII |
CA3090795A1 (en) | 2018-02-13 | 2019-08-22 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists |
EP3752195A4 (en) | 2018-02-14 | 2021-11-17 | Viela Bio, Inc. | Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases |
US11685781B2 (en) | 2018-02-15 | 2023-06-27 | Macrogenics, Inc. | Variant CD3-binding domains and their use in combination therapies for the treatment of disease |
BR112020017925A2 (en) | 2018-03-02 | 2020-12-22 | Five Prime Therapeutics, Inc. | ANTIBODIES AGAINST B7-H4 AND METHODS OF USE OF THE SAME |
CA3093729A1 (en) | 2018-03-15 | 2019-09-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use |
WO2019183209A1 (en) | 2018-03-20 | 2019-09-26 | Synthetic Biologics, Inc. | Alkaline phosphatase agents for treatment of radiation disorders |
CA3094098A1 (en) * | 2018-03-21 | 2019-09-26 | ALX Oncology Inc. | Antibodies against signal-regulatory protein alpha and methods of use |
CN112384527B (en) | 2018-03-23 | 2023-06-27 | 布鲁塞尔自由大学 | Wnt signaling agonist molecules |
KR20210002499A (en) | 2018-03-28 | 2021-01-08 | 다케다 야쿠힌 고교 가부시키가이샤 | Subcutaneous administration of anti-CD38 antibody |
EA202092316A1 (en) | 2018-03-28 | 2021-05-25 | Бристол-Маерс Сквибб Компани | FUSION PROTEINS OF INTERLEUKIN-2 / ALPHA-RECEPTOR OF INTERLEUKIN-2 AND METHODS OF APPLICATION |
JP2021524756A (en) | 2018-05-14 | 2021-09-16 | ウェアウルフ セラピューティクス, インコーポレイテッド | Activateable cytokine polypeptides and how to use them |
ES2955511T3 (en) | 2018-05-14 | 2023-12-04 | Werewolf Therapeutics Inc | Activatable interleukin 2 polypeptides and methods of use thereof |
KR20210013091A (en) | 2018-05-16 | 2021-02-03 | 시에스엘 리미티드 | Soluble complement receptor type 1 variant and uses thereof |
MA52630A (en) | 2018-05-18 | 2021-05-26 | Bioverativ Therapeutics Inc | HEMOPHILIA A TREATMENT METHODS |
EP3800999A4 (en) | 2018-06-04 | 2022-06-01 | Biogen MA Inc. | Anti-vla-4 antibodies having reduced effector function |
TW202016151A (en) | 2018-06-09 | 2020-05-01 | 德商百靈佳殷格翰國際股份有限公司 | Multi-specific binding proteins for cancer treatment |
GB201809746D0 (en) | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
CA3102841A1 (en) | 2018-06-15 | 2019-12-19 | Proclara Biosciences, Inc. | General amyloid interaction motif (gaim) |
SG11202012257VA (en) | 2018-06-26 | 2021-01-28 | Immunogen Inc | Immunoconjugates targeting adam9 and methods of use thereof |
JP2021529763A (en) | 2018-07-03 | 2021-11-04 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | FGF-21 preparation |
WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
MX2021000488A (en) | 2018-07-19 | 2021-04-12 | Regeneron Pharma | BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF. |
EP3833766A1 (en) | 2018-08-09 | 2021-06-16 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
WO2020047319A1 (en) | 2018-08-29 | 2020-03-05 | Shattuck Labs, Inc. | Combination therapies comprising sirp alpha-based chimeric proteins |
US11401324B2 (en) * | 2018-08-30 | 2022-08-02 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
JP7397874B2 (en) | 2018-08-30 | 2023-12-13 | エイチシーダブリュー バイオロジックス インコーポレイテッド | Multichain chimeric polypeptides and their uses |
AU2019328575A1 (en) | 2018-08-30 | 2021-02-25 | HCW Biologics, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
US20220119782A1 (en) * | 2018-08-31 | 2022-04-21 | Yale University | ENPP1 Polypeptides and Methods of Using Same |
TW202031273A (en) | 2018-08-31 | 2020-09-01 | 美商艾歐凡斯生物治療公司 | Treatment of nsclc patients refractory for anti-pd-1 antibody |
JP2022502088A (en) | 2018-09-27 | 2022-01-11 | エクシリオ デベロップメント, インコーポレイテッド | Masked cytokine polypeptide |
CN112969503A (en) | 2018-10-03 | 2021-06-15 | 斯塔滕生物技术有限公司 | Antibodies specific for human and cynomolgus macaques APOC3 and methods of use thereof |
TW202029980A (en) | 2018-10-26 | 2020-08-16 | 美商免疫遺傳股份有限公司 | Epcam antibodies, activatable antibodies, and immunoconjugates, and uses thereof |
CA3118397A1 (en) | 2018-11-01 | 2020-05-07 | Shandong Newtime Pharmaceutical Co., Ltd. | Bispecific antibody targeting cd3 and bcma, and uses thereof |
KR20210091212A (en) | 2018-11-05 | 2021-07-21 | 이오반스 바이오테라퓨틱스, 인크. | Treatment of NSCLC Patients Refractory to Anti-PD-1 Antibodies |
US11827670B2 (en) | 2018-11-09 | 2023-11-28 | University Of Massachusetts | Anti-CfaE antibodies and methods of use |
PE20211284A1 (en) | 2018-11-16 | 2021-07-19 | Bristol Myers Squibb Co | ANTI-NKG2A ANTIBODIES AND USES OF THEM |
JP2022513653A (en) | 2018-11-28 | 2022-02-09 | ブリストル-マイヤーズ スクイブ カンパニー | Antibodies containing modified heavy chain constant regions |
CN113227134A (en) | 2018-12-05 | 2021-08-06 | 株式会社梅花治疗 | Fc region variants of antibodies |
WO2020118011A1 (en) | 2018-12-06 | 2020-06-11 | Alexion Pharmaceuticals, Inc. | Anti-alk2 antibodies and uses thereof |
WO2020115283A1 (en) | 2018-12-07 | 2020-06-11 | Baxalta GmbH | Bispecific antibodies binding factor ixa and factor x |
TW202039583A (en) | 2018-12-07 | 2020-11-01 | 瑞士商巴克斯歐塔有限公司 | Proteinaceous molecules binding factor ixa and factor x |
WO2020114616A1 (en) | 2018-12-07 | 2020-06-11 | Tillotts Pharma Ag | Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof |
CA3123177A1 (en) | 2018-12-21 | 2020-06-25 | Kymab Limited | Fixaxfx bispecific antibody with common light chain |
EP3902833A2 (en) | 2018-12-26 | 2021-11-03 | City of Hope | Activatable masked anti-ctla4 binding proteins |
CN113227135A (en) | 2018-12-28 | 2021-08-06 | 斯帕克斯治疗公司 | Binding molecules specific for claudin 18.2, compositions and methods thereof for the treatment of cancer and other diseases |
MX2021008081A (en) | 2019-01-04 | 2021-08-05 | Resolve Therapeutics Llc | Treatment of sjogren's disease with nuclease fusion proteins. |
AU2020211728A1 (en) | 2019-01-23 | 2021-08-12 | Encefa | CD31 competitors and uses thereof |
JOP20210233A1 (en) | 2019-02-26 | 2023-01-30 | Janssen Biotech Inc | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
MA55080A (en) | 2019-02-26 | 2022-01-05 | Inspirna Inc | HIGH AFFINITY ANTI-MERTK ANTIBODIES AND ASSOCIATED USES |
KR20210136050A (en) | 2019-03-01 | 2021-11-16 | 이오반스 바이오테라퓨틱스, 인크. | Expansion of tumor-infiltrating lymphocytes from liquid tumors and their therapeutic use |
EP3934689A1 (en) | 2019-03-05 | 2022-01-12 | Prothena Biosciences Limited | Methods of treating al amyloidosis |
US20220153875A1 (en) | 2019-03-19 | 2022-05-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain |
MA55529A (en) | 2019-04-03 | 2022-02-09 | Genzyme Corp | REDUCED FRAGMENTATION ANTI-ALPHA BETA TCR BINDING POLYPEPTIDES |
GB2589049C (en) | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
EP3962942A1 (en) | 2019-05-01 | 2022-03-09 | Novo Nordisk A/S | Anti-il-6 antibody formulation |
JOP20210304A1 (en) | 2019-05-14 | 2023-01-30 | Janssen Biotech Inc | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors |
JP2022532217A (en) | 2019-05-14 | 2022-07-13 | ウェアウルフ セラピューティクス, インコーポレイテッド | Separation part and how to use it |
MA56102A (en) | 2019-06-07 | 2022-04-13 | Argenx Bvba | PHARMACEUTICAL FORMULATIONS OF FCRN INHIBITORS SUITABLE FOR SUBCUTANEOUS ADMINISTRATION |
US20220259329A1 (en) | 2019-06-07 | 2022-08-18 | Amgen Inc. | Bispecific binding constructs |
JP2022537134A (en) | 2019-06-10 | 2022-08-24 | 武田薬品工業株式会社 | Combination therapy using CD38 antibody |
JP2022537369A (en) | 2019-06-18 | 2022-08-25 | バイエル アクチェンゲゼルシャフト | Adrenomedullin-analogs and their use for long-term stabilization |
US11738052B2 (en) | 2019-06-21 | 2023-08-29 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
WO2021021615A1 (en) | 2019-07-26 | 2021-02-04 | Shire Human Genetic Therapies, Inc. | Recombinant heme oxygenase-1 (ho-1) for the treatment of sickle cell disease |
CN114502593A (en) | 2019-08-06 | 2022-05-13 | 葛兰素史密斯克莱知识产权发展有限公司 | Biopharmaceutical compositions and related methods |
US20220242962A1 (en) | 2019-08-12 | 2022-08-04 | Aptevo Research And Development Llc | 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40 |
EP4013774A1 (en) | 2019-08-13 | 2022-06-22 | Elpis Biopharmaceuticals | Engineered interleukin-2 receptor beta agonists |
US11680098B2 (en) | 2019-08-30 | 2023-06-20 | Agenus Inc. | Antibodies that specifically bind human CD96 |
US20210113634A1 (en) | 2019-09-30 | 2021-04-22 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
JP2023501229A (en) | 2019-11-15 | 2023-01-18 | エンテラ・エッセ・エッレ・エッレ | TMEM219 antibody and its therapeutic use |
WO2021099574A1 (en) | 2019-11-21 | 2021-05-27 | Enthera S.R.L. | Igfbp3 antibodies and therapeutic uses thereof |
EP4065607A1 (en) | 2019-11-29 | 2022-10-05 | Kymab Limited | Treatment for physiological iron overload |
CA3164818A1 (en) | 2019-12-18 | 2021-06-24 | F. Hoffmann-La Roche Ag | Bispecific anti-ccl2 antibodies |
CA3163172A1 (en) | 2020-01-08 | 2021-07-15 | Peter Verheesen | Methods for treating pemphigus disorders |
CN115362167A (en) | 2020-02-06 | 2022-11-18 | 百时美施贵宝公司 | IL-10 and uses thereof |
EP3868396A1 (en) | 2020-02-20 | 2021-08-25 | Enthera S.R.L. | Inhibitors and uses thereof |
IL295590A (en) | 2020-02-28 | 2022-10-01 | Genzyme Corp | Modified binding polypeptides for optimized drug conjugation |
US11365239B2 (en) | 2020-03-20 | 2022-06-21 | Tsb Therapeutics (Beijing) Co., Ltd. | Anti-SARS-COV-2 antibodies and uses thereof |
US20230174626A1 (en) | 2020-03-27 | 2023-06-08 | Glaxosmithkline Biologicals Sa | Antibodies |
WO2021202463A1 (en) | 2020-03-30 | 2021-10-07 | Danisco Us Inc | Anti-rsv antibodies |
JP2023522102A (en) | 2020-04-20 | 2023-05-26 | ジェンザイム・コーポレーション | Humanized anti-complement factor Bb antibody and uses thereof |
WO2021217024A1 (en) | 2020-04-24 | 2021-10-28 | Millennium Pharmaceuticals, Inc. | Anti-cd19 antibodies and uses thereof |
WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
JP2023528235A (en) | 2020-05-17 | 2023-07-04 | アストラゼネカ・ユーケイ・リミテッド | SARS-CoV-2 Antibodies and Methods of Selecting and Using The Same |
JP2023526540A (en) | 2020-05-22 | 2023-06-21 | フォーマイコン アーゲー | ACE2 fusion proteins and methods of use thereof |
EP4161969A1 (en) | 2020-06-04 | 2023-04-12 | Amgen Inc. | Bispecific binding constructs |
WO2021251438A1 (en) | 2020-06-10 | 2021-12-16 | 株式会社バイカ・セラピュティクス | Fusion protein containing erythropoietin polypeptide |
CA3186143A1 (en) | 2020-06-17 | 2021-12-23 | Medimmune Limited | Heterodimeric relaxin fusions and uses thereof |
KR20230023803A (en) * | 2020-06-23 | 2023-02-17 | 매든 어드바이저스 엘엘씨 | Anti-CCR5 monoclonal antibody-based compositions and methods |
JP2023532266A (en) | 2020-06-23 | 2023-07-27 | ジアンスー カニョン ファーマシューティカル カンパニー リミテッド | Anti-CD38 antibody and use thereof |
EP4171614A1 (en) | 2020-06-29 | 2023-05-03 | Resolve Therapeutics, LLC | Treatment of sjogren's syndrome with nuclease fusion proteins |
EP4175650A1 (en) | 2020-07-06 | 2023-05-10 | Kiromic BioPharma, Inc. | Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof |
AR122933A1 (en) | 2020-07-10 | 2022-10-19 | Novo Nordisk As | METHODS TO TREAT CARDIOVASCULAR DISEASE |
WO2022031978A1 (en) | 2020-08-06 | 2022-02-10 | Bioverativ Usa Inc. | Inflammatory cytokines and fatigue in subject with a complement mediated disease |
US20220041694A1 (en) | 2020-08-10 | 2022-02-10 | Astrazeneca Uk Limited | Sars-cov-2 antibodies for treatment and prevention of covid-19 |
CN116761821A (en) | 2020-08-18 | 2023-09-15 | 赛福伦有限责任公司 | anti-PAR-2 antibodies and methods of use thereof |
AU2021336259A1 (en) | 2020-09-01 | 2023-03-30 | Takeda Pharmaceutical Company Limited | Interleukin-2 muteins and uses thereof |
BR112023004415A2 (en) | 2020-09-11 | 2023-05-09 | Medimmune Ltd | B7-H4 BINDING THERAPEUTIC MOLECULES |
DE102020125457A1 (en) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidated peptides and their deamidated counterparts presented by HLA-A*02 molecules for use in immunotherapy against various types of cancer |
DE102020125465A1 (en) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidated peptides and their deamidated counterparts presented by non-HLA-A*02 molecules for use in immunotherapy against various types of cancer |
TW202229312A (en) | 2020-09-29 | 2022-08-01 | 德商英麥提克生物技術股份有限公司 | Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancers |
WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
EP4225330A1 (en) | 2020-10-06 | 2023-08-16 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
TW202228775A (en) * | 2020-10-14 | 2022-08-01 | 美商維里迪恩醫療股份有限公司 | Compositions and methods for treatment of thyroid eye disease |
AU2021367988A1 (en) | 2020-10-29 | 2023-05-11 | Formycon Ag | Ace2 fusion proteins and uses thereof |
WO2022108627A1 (en) | 2020-11-18 | 2022-05-27 | Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. | Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules |
MX2023006426A (en) | 2020-12-01 | 2023-07-17 | Aptevo Res And Development Llc | Heterodimeric psma and cd3-binding bispecific antibodies. |
KR20230117397A (en) | 2020-12-03 | 2023-08-08 | 암젠 인크 | Molecules with Multiple Binding Domains |
JP2023552462A (en) * | 2020-12-08 | 2023-12-15 | ジャナックス セラピューティクス,インク. | Half-life extension compositions and methods |
KR20230135575A (en) | 2020-12-09 | 2023-09-25 | 재눅스 테라퓨틱스 인크. | Compositions and methods related to tumor-activating antibodies targeting PSMA and effector cell antigens |
WO2022125941A1 (en) | 2020-12-11 | 2022-06-16 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors |
WO2022133149A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocytes |
JP2023554395A (en) | 2020-12-17 | 2023-12-27 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Treatment with tumor-infiltrating lymphocyte therapy in combination with CTLA-4 and PD-1 inhibitors |
AU2021399453A1 (en) | 2020-12-18 | 2023-07-27 | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Respiratory syncytial virus-specific binding molecule |
JP2024501845A (en) | 2020-12-31 | 2024-01-16 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Devices and processes for automated production of tumor-infiltrating lymphocytes |
TW202241925A (en) | 2021-01-15 | 2022-11-01 | 德商英麥提克生物技術股份有限公司 | Peptides displayed by hla for use in immunotherapy against different types of cancers |
KR20230148169A (en) | 2021-01-22 | 2023-10-24 | 엘피스 바이오파마슈티컬즈 | Anti-PD-L1 monoclonal antibody and interleukin-15 (IL-15), interleukin-15 receptor 15 alpha or fusion protein with interleukin-2 |
WO2022165260A1 (en) | 2021-01-29 | 2022-08-04 | Iovance Biotherapeutics, Inc. | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy |
TW202317612A (en) | 2021-03-01 | 2023-05-01 | 美商艾希利歐發展股份有限公司 | Combination of ctla4 and pd1/pdl1 antibodies for treating cancer |
EP4301781A1 (en) | 2021-03-01 | 2024-01-10 | Xilio Development, Inc. | Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer |
WO2022184854A2 (en) | 2021-03-03 | 2022-09-09 | Formycon Ag | Formulations of ace2 fc fusion proteins |
EP4301138A2 (en) | 2021-03-05 | 2024-01-10 | Iovance Biotherapeutics, Inc. | Tumor storage and cell culture compositions |
CA3212439A1 (en) | 2021-03-19 | 2022-09-22 | Michelle SIMPSON-ABELSON | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils |
CA3213080A1 (en) | 2021-03-23 | 2022-09-29 | Krit RITTHIPICHAI | Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
KR20240032711A (en) | 2021-03-25 | 2024-03-12 | 이오반스 바이오테라퓨틱스, 인크. | Methods and compositions for use in T-cell co-culture efficacy assays and cell therapeutics |
WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
WO2022207785A1 (en) | 2021-03-31 | 2022-10-06 | Kymab Limited | Antibodies to gfral |
CA3215737A1 (en) | 2021-03-31 | 2022-10-06 | Cambridge Enterprise Limited | Therapeutic inhibitors of gdf15 signalling |
EP4313296A1 (en) | 2021-03-31 | 2024-02-07 | Bioverativ USA Inc. | Reducing surgery-associated hemolysis in cold agglutinin disease patients |
CN117425673A (en) | 2021-04-09 | 2024-01-19 | 武田药品工业株式会社 | Antibodies targeting complement factor D and uses thereof |
KR20240037185A (en) | 2021-04-19 | 2024-03-21 | 이오반스 바이오테라퓨틱스, 인크. | Chimeric costimulatory receptors, chemokine receptors, and their uses in cellular immunotherapy |
KR20240004286A (en) | 2021-04-26 | 2024-01-11 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Anti-Clec12A antibodies and uses thereof |
EP4330283A1 (en) | 2021-04-26 | 2024-03-06 | Millennium Pharmaceuticals, Inc. | Anti-adgre2 antibodies and uses thereof |
EP4340850A1 (en) | 2021-05-17 | 2024-03-27 | Iovance Biotherapeutics, Inc. | Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy |
BR112023024804A2 (en) | 2021-05-28 | 2024-02-15 | Glaxosmithkline Ip Dev Ltd | COMBINATION THERAPIES TO TREAT CANCER |
WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
IL309349A (en) | 2021-06-14 | 2024-02-01 | argenx BV | Anti-il-9 antibodies and methods of use thereof |
CA3221735A1 (en) | 2021-06-18 | 2022-12-22 | F. Hoffmann-La Roche Ag | Bispecific anti-ccl2 antibodies |
CA3221555A1 (en) | 2021-06-23 | 2022-12-29 | Kimberly LONG | A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders |
CA3226111A1 (en) | 2021-07-22 | 2023-01-26 | Iovance Biotherapeutics, Inc. | Method for cryopreservation of solid tumor fragments |
WO2023009716A1 (en) | 2021-07-28 | 2023-02-02 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
KR20240040786A (en) | 2021-08-03 | 2024-03-28 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Biopharmaceutical compositions and stable isotope labeled peptide mapping methods |
CA3229251A1 (en) * | 2021-08-16 | 2023-02-23 | Aaron RING | Interleukin-12 variants and methods of use |
AU2022329459A1 (en) | 2021-08-20 | 2024-02-29 | Intervet International B.V. | Antibodies and igg fusion proteins with an extended half-life |
AU2022332285A1 (en) | 2021-08-23 | 2024-02-15 | Immunitas Therapeutics, Inc. | Anti-cd161 antibodies and uses thereof |
CN117881784A (en) | 2021-08-31 | 2024-04-12 | 大正制药株式会社 | Anti-growth hormone antibodies |
AU2022343729A1 (en) | 2021-09-09 | 2024-03-21 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1 talen knockdown |
WO2023049862A1 (en) | 2021-09-24 | 2023-03-30 | Iovance Biotherapeutics, Inc. | Expansion processes and agents for tumor infiltrating lymphocytes |
CA3232806A1 (en) | 2021-09-30 | 2023-04-06 | Seagen Inc. | B7-h4 antibody-drug conjugates for the treatment of cancer |
CA3233953A1 (en) | 2021-10-05 | 2023-04-13 | Matthew Bruce | Combination therapies for treating cancer |
AU2022372894A1 (en) | 2021-10-20 | 2024-04-18 | Takeda Pharmaceutical Company Limited | Compositions targeting bcma and methods of use thereof |
AR127482A1 (en) | 2021-10-27 | 2024-01-31 | Iovance Biotherapeutics Inc | SYSTEMS AND METHODS TO COORDINATE THE MANUFACTURE OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY |
TW202342095A (en) | 2021-11-05 | 2023-11-01 | 英商阿斯特捷利康英國股份有限公司 | Composition for treatment and prevention of covid-19 |
WO2023086803A1 (en) | 2021-11-10 | 2023-05-19 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
CA3235096A1 (en) | 2021-11-17 | 2023-05-25 | Disc Medicine, Inc. | Methods for treating anemia of kidney disease |
WO2023094507A1 (en) | 2021-11-24 | 2023-06-01 | Formycon Ag | Improved ace2 fusion proteins |
WO2023094571A1 (en) | 2021-11-25 | 2023-06-01 | Formycon Ag | Stabilization of ace2 fusion proteins |
WO2023111112A1 (en) | 2021-12-15 | 2023-06-22 | Medimmune Limited | Treatment using heterodimeric relaxin fusions |
WO2023114951A1 (en) | 2021-12-17 | 2023-06-22 | Viiv Healthcare Company | Combination therapies for hiv infections and uses thereof |
WO2023139107A1 (en) | 2022-01-18 | 2023-07-27 | argenx BV | Galectin-10 antibodies |
WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
WO2023147486A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
TW202348252A (en) | 2022-02-16 | 2023-12-16 | 英商梅迪繆思有限公司 | Combination therapies for treatment of cancer with therapeutic binding molecules |
WO2023168352A1 (en) | 2022-03-03 | 2023-09-07 | Yale University | Humanized 3e10 antibodies, variants, and antigen binding fragments thereof |
WO2023169896A1 (en) | 2022-03-09 | 2023-09-14 | Astrazeneca Ab | BINDING MOLECULES AGAINST FRα |
WO2023170216A1 (en) | 2022-03-11 | 2023-09-14 | Astrazeneca Ab | A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY |
WO2023196877A1 (en) | 2022-04-06 | 2023-10-12 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
WO2023212304A1 (en) | 2022-04-29 | 2023-11-02 | 23Andme, Inc. | Antigen binding proteins |
WO2023209177A1 (en) | 2022-04-29 | 2023-11-02 | Astrazeneca Uk Limited | Sars-cov-2 antibodies and methods of using the same |
US11780910B1 (en) | 2022-05-02 | 2023-10-10 | Novo Nordisk A/S | Anti-ANGPTL3 antibodies suitable for high concentration compositions and subcutaneous administration |
WO2023220597A1 (en) | 2022-05-10 | 2023-11-16 | Elpis Biopharmaceuticals | Engineered interleukin-2 receptor beta reduced-binding agonist |
WO2023220608A1 (en) | 2022-05-10 | 2023-11-16 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist |
WO2023242372A1 (en) | 2022-06-15 | 2023-12-21 | argenx BV | Fcrn/hsa binding molecules and methods of use |
WO2023245048A1 (en) | 2022-06-15 | 2023-12-21 | Bioverativ Usa Inc. | Anti-complement c1s antibody formulation |
WO2023250507A1 (en) | 2022-06-24 | 2023-12-28 | Bioverativ Usa Inc. | Methods for treating complement-mediated diseases |
WO2024011114A1 (en) | 2022-07-06 | 2024-01-11 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
WO2024015830A1 (en) | 2022-07-12 | 2024-01-18 | Cytomx Therapeutics, Inc. | Epcam immunoconjugates and uses thereof |
US20240034780A1 (en) | 2022-07-22 | 2024-02-01 | Flagship Pioneering Innovations Vi, Llc | Antigen Binding Molecules Targeting Thymic Stromal Lymphopoietin (TSLP) |
WO2024026395A1 (en) | 2022-07-27 | 2024-02-01 | Cephalon Llc | Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease |
WO2024026386A1 (en) | 2022-07-27 | 2024-02-01 | Cephalon Llc | Anti-tl1a antibody formulations |
US20240052051A1 (en) | 2022-07-29 | 2024-02-15 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:payload fusions and methods of use thereof |
WO2024026494A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Viral particles retargeted to transferrin receptor 1 |
WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
WO2024030758A1 (en) | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
WO2024038193A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
WO2024038183A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
WO2024042112A1 (en) | 2022-08-25 | 2024-02-29 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins and uses thereof |
WO2024050421A2 (en) | 2022-08-30 | 2024-03-07 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting programmed cell death protein 1 (pd-1) |
US20240101691A1 (en) | 2022-09-21 | 2024-03-28 | Sanofi Biotechnology | Humanized anti-il-1r3 antibody and methods of use |
Family Cites Families (170)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
ATE37983T1 (en) | 1982-04-22 | 1988-11-15 | Ici Plc | DELAYED RELEASE AGENT. |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4666884A (en) | 1984-04-10 | 1987-05-19 | New England Deaconess Hospital | Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
WO1989007142A1 (en) | 1988-02-05 | 1989-08-10 | Morrison Sherie L | Domain-modified constant region antibodies |
US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
DE768377T1 (en) | 1988-09-02 | 1998-01-02 | Dyax Corp | Production and selection of recombinant proteins with different binding sites |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
KR900005995A (en) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | Modified Interleukin-2 and Method of Making the Same |
KR0184860B1 (en) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | Single domain ligands receptors comprising said ligands methods for their production and use of said ligands |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
DE69029036T2 (en) | 1989-06-29 | 1997-05-22 | Medarex Inc | SPECIFIC REAGENTS FOR AIDS THERAPY |
US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
AU6430190A (en) | 1989-10-10 | 1991-05-16 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
JP2571874B2 (en) | 1989-11-06 | 1997-01-16 | アルカーメス コントロールド セラピューティクス,インコーポレイテッド | Protein microsphere composition |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
DE69120146T2 (en) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | GENERATION OF XENOGENIC ANTIBODIES |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
CA2078689C (en) | 1990-03-20 | 2003-02-11 | Sherie L. Morrison | Chimeric antibodies with receptor binding ligands in place of their constant region |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ES2246502T3 (en) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES. |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
CA2092323A1 (en) | 1990-10-01 | 1992-04-02 | George Y. Wu | Targeting viruses and cells for selective internalization by cells |
ES2129029T5 (en) | 1990-10-05 | 2005-10-16 | Celldex Therapeutics, Inc. | DIRECT IMMUNOSTIMULATION WITH BISPECIFIC REAGENTS. |
AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
ES2113940T3 (en) | 1990-12-03 | 1998-05-16 | Genentech Inc | ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES. |
WO1992010591A1 (en) | 1990-12-14 | 1992-06-25 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
AU660981B2 (en) * | 1991-03-12 | 1995-07-13 | Astellas Us Llc | CD2-binding domain of lymphocyte function associated antigen 3 |
DE69233750D1 (en) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Libraries of heterodimeric receptors using phagemids |
DE69214709T2 (en) | 1991-04-26 | 1997-02-20 | Surface Active Ltd | New antibodies and methods of using them |
JPH06507404A (en) | 1991-05-01 | 1994-08-25 | ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン | How to treat infectious respiratory diseases |
JPH06510524A (en) | 1991-05-14 | 1994-11-24 | ユニバーシティ オブ コネチカット | Targeted delivery of genes encoding immunogenic proteins |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
DK0587738T3 (en) | 1991-06-05 | 2000-12-18 | Univ Connecticut | Destined delivery of genes encoding secretory proteins |
AU2238292A (en) | 1991-06-14 | 1993-01-12 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
ES2136092T3 (en) | 1991-09-23 | 1999-11-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES. |
DK1024191T3 (en) | 1991-12-02 | 2008-12-08 | Medical Res Council | Preparation of autoantibodies displayed on phage surfaces from antibody segment libraries |
US20020102257A1 (en) | 1998-09-21 | 2002-08-01 | Leslie Sid Johnson | Human-murine chimeric antibodies against respiratory syncytial virus |
US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
AU3434393A (en) | 1992-01-17 | 1993-08-03 | Regents Of The University Of Michigan, The | Targeted virus |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
EP0627940B1 (en) | 1992-03-05 | 2003-05-07 | Board of Regents, The University of Texas System | Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
WO1993020221A1 (en) | 1992-04-03 | 1993-10-14 | Young Alexander T | Gene therapy using targeted viral vectors |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
DE69325777T2 (en) | 1992-06-09 | 2000-03-09 | Hoppe Ag | LATCH AND DOOR LOCK |
CA2141602A1 (en) | 1992-08-26 | 1994-03-03 | Philip Leder | Use of the cytokine ip-10 as an anti-tumor agent |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
DK0671923T3 (en) | 1992-10-09 | 2001-08-13 | Advanced Tissue Sciences Inc | Liver reserve cells |
AU680459B2 (en) | 1992-12-03 | 1997-07-31 | Genzyme Corporation | Gene therapy for cystic fibrosis |
US5441050A (en) | 1992-12-18 | 1995-08-15 | Neoprobe Corporation | Radiation responsive surgical instrument |
EP1262564A3 (en) | 1993-01-07 | 2004-03-31 | Sequenom, Inc. | Dna sequencing by mass spectrometry |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
JPH08511420A (en) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | Body |
EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
DK0744958T3 (en) | 1994-01-31 | 2003-10-20 | Univ Boston | Polyclonal antibody libraries |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
GB9415379D0 (en) | 1994-07-29 | 1994-09-21 | Smithkline Beecham Plc | Novel compounds |
CA2196200A1 (en) | 1994-07-29 | 1996-02-15 | Michael Joseph Browne | Novel compounds |
WO1996020698A2 (en) | 1995-01-05 | 1996-07-11 | The Board Of Regents Acting For And On Behalf Of The University Of Michigan | Surface-modified nanoparticles and method of making and using same |
EP1323346B1 (en) | 1995-01-17 | 2006-06-28 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US5739277A (en) * | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) * | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5747035A (en) | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
ES2304786T3 (en) | 1995-04-27 | 2008-10-16 | Amgen Fremont Inc. | ANTI-IL-8 HUMAN ANTIBODIES, DERIVED FROM IMMUNIZED XENORATONES. |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | Human antibodies derived from immunized xenomice |
US5811524A (en) * | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
EP0850051A2 (en) | 1995-08-31 | 1998-07-01 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
JP2978435B2 (en) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | Method for producing acryloxypropyl silane |
US5985320A (en) | 1996-03-04 | 1999-11-16 | The Penn State Research Foundation | Materials and methods for enhancing cellular internalization |
WO1997033899A1 (en) | 1996-03-14 | 1997-09-18 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
DE69731289D1 (en) * | 1996-03-18 | 2004-11-25 | Univ Texas | IMMUNGLOBULIN-LIKE DOMAIN WITH INCREASED HALF-VALUE TIMES |
CA2248868A1 (en) | 1996-03-22 | 1997-09-25 | Human Genome Sciences, Inc. | Apoptosis inducing molecule ii |
WO1997043316A1 (en) | 1996-05-10 | 1997-11-20 | Beth Israel Deaconess Medical Center, Inc. | Physiologically active molecules with extended half-lives and methods of using same |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
DK1500329T3 (en) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Human antibodies that specifically bind TNF-alpha |
PT954282E (en) | 1997-01-16 | 2005-06-30 | Massachusetts Inst Technology | PREPARATION OF PARTICLES FOR INHALATION |
US6590079B2 (en) | 1997-01-30 | 2003-07-08 | Ixsys, Incorporated | Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same |
US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
WO1998046645A2 (en) | 1997-04-14 | 1998-10-22 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | Method for the production of antihuman antigen receptors and uses thereof |
DE69830901T2 (en) * | 1997-05-02 | 2006-05-24 | Genentech Inc., San Francisco | A method for producing multispecific antibodies having heteromultimeric and common components |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US6133166A (en) | 1997-07-01 | 2000-10-17 | The Procter & Gamble Company | Cleaning articles comprising a cellulosic fibrous structure having discrete basis weight regions treated with a high internal phase inverse emulsion |
US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
SE512663C2 (en) | 1997-10-23 | 2000-04-17 | Biogram Ab | Active substance encapsulation process in a biodegradable polymer |
EP1992633A1 (en) | 1997-11-03 | 2008-11-19 | Human Genome Sciences, Inc. | VEGI, an inhibitor of angiogenesis and tumor growth |
JP2002505086A (en) | 1998-02-25 | 2002-02-19 | レキシジェン ファーマシューティカルズ コーポレイション | Enhanced circulating half-life of antibody-based fusion proteins |
US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ATE375365T1 (en) | 1998-04-02 | 2007-10-15 | Genentech Inc | ANTIBODIES VARIANTS AND FRAGMENTS THEREOF |
US6528624B1 (en) * | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
CA2336139C (en) | 1998-06-24 | 2008-10-14 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
US6572856B1 (en) * | 1998-09-10 | 2003-06-03 | The University Of Virginia Patent Foundation | Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
US6531580B1 (en) | 1999-06-24 | 2003-03-11 | Ixsys, Inc. | Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same |
US6656467B2 (en) | 2000-01-27 | 2003-12-02 | Medimmune, Inc. | Ultra high affinity neutralizing antibodies |
US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
ES2269366T3 (en) | 2000-02-11 | 2007-04-01 | Merck Patent Gmbh | IMPROVEMENT OF AVERAGE LIFE IN CIRCULATION OF FUSION PROTEINS BASED ON ANTIBODIES. |
ES2390761T3 (en) | 2000-03-01 | 2012-11-16 | Medimmune, Llc | Recombinant high-potency antibodies and method for their production |
AU5345901A (en) * | 2000-04-13 | 2001-10-30 | Univ Rockefeller | Enhancement of antibody-mediated immune responses |
US6855493B2 (en) | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
US7179900B2 (en) | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
US6818216B2 (en) | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
US7658921B2 (en) * | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
EP2341060B1 (en) * | 2000-12-12 | 2019-02-20 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
US20030199671A1 (en) | 2001-04-18 | 2003-10-23 | Rondon Isaac Jesus | Binding molecules for Fc-region polypeptides |
US6911321B2 (en) | 2001-12-19 | 2005-06-28 | Genentech, Inc. | Non-human primate Fc receptors and methods of use |
US7219797B2 (en) * | 2002-01-14 | 2007-05-22 | Alliance Packaging Llc. | Box with insert that extends from a side and that divides the box into compartments and methods for forming and using |
US20040002587A1 (en) * | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
EP1534335B9 (en) | 2002-08-14 | 2016-01-13 | Macrogenics, Inc. | Fcgammariib-specific antibodies and methods of use thereof |
BRPI0314814C1 (en) | 2002-09-27 | 2021-07-27 | Xencor Inc | antibody comprising an fc variant |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
PT1562972E (en) | 2002-10-15 | 2010-11-10 | Facet Biotech Corp | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7365168B2 (en) | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
CA2545539A1 (en) | 2003-10-15 | 2005-04-28 | Pdl Biopharma, Inc. | Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig |
EP1812068A4 (en) * | 2004-10-29 | 2010-06-09 | Medimmune Inc | Methods of preventing and treating rsv infections and related conditions |
EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
US8775090B2 (en) | 2008-12-12 | 2014-07-08 | Medimmune, Llc | Crystals and structure of a human IgG Fc variant with enhanced FcRn binding |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
-
2001
- 2001-12-12 EP EP10010679.8A patent/EP2341060B1/en not_active Expired - Lifetime
- 2001-12-12 EP EP19153658.0A patent/EP3569610A3/en not_active Withdrawn
- 2001-12-12 EP EP10010680.6A patent/EP2354149B1/en not_active Expired - Lifetime
- 2001-12-12 US US10/020,354 patent/US7083784B2/en not_active Expired - Lifetime
- 2001-12-12 DE DE60143544T patent/DE60143544D1/en not_active Expired - Lifetime
- 2001-12-12 ES ES10010679T patent/ES2727425T3/en not_active Expired - Lifetime
- 2001-12-12 WO PCT/US2001/048432 patent/WO2002060919A2/en active Search and Examination
- 2001-12-12 EP EP01997063A patent/EP1355919B1/en not_active Expired - Lifetime
- 2001-12-12 PT PT01997063T patent/PT1355919E/en unknown
- 2001-12-12 ES ES10010680.6T patent/ES2649037T3/en not_active Expired - Lifetime
- 2001-12-12 AU AU2002248184A patent/AU2002248184C1/en not_active Expired
- 2001-12-12 DK DK01997063.1T patent/DK1355919T3/en active
- 2001-12-12 AT AT01997063T patent/ATE489395T1/en active
- 2001-12-12 JP JP2002561487A patent/JP4336498B2/en not_active Expired - Lifetime
- 2001-12-12 CA CA2431600A patent/CA2431600C/en not_active Expired - Lifetime
- 2001-12-12 EP EP10010681A patent/EP2357187A1/en not_active Withdrawn
-
2006
- 2006-04-03 US US11/397,328 patent/US7670600B2/en not_active Expired - Lifetime
-
2007
- 2007-01-03 US US11/649,455 patent/US7704497B2/en not_active Expired - Lifetime
- 2007-08-27 JP JP2007219930A patent/JP4336376B2/en not_active Expired - Lifetime
-
2009
- 2009-05-08 JP JP2009113588A patent/JP5265446B2/en not_active Expired - Lifetime
-
2010
- 2010-01-04 JP JP2010000073A patent/JP5444010B2/en not_active Expired - Lifetime
- 2010-01-21 US US12/691,433 patent/US8012476B2/en not_active Expired - Fee Related
-
2011
- 2011-02-24 CY CY20111100229T patent/CY1111283T1/en unknown
- 2011-07-27 US US13/192,429 patent/US8323962B2/en not_active Expired - Lifetime
-
2012
- 2012-10-24 US US13/659,144 patent/US8475792B2/en not_active Expired - Lifetime
-
2013
- 2013-05-20 US US13/898,042 patent/US8795661B2/en not_active Expired - Fee Related
- 2013-08-16 JP JP2013169026A patent/JP6125949B2/en not_active Expired - Lifetime
-
2014
- 2014-06-20 US US14/310,507 patent/US9562100B2/en not_active Expired - Lifetime
-
2015
- 2015-07-13 JP JP2015139342A patent/JP6268127B2/en not_active Expired - Lifetime
-
2016
- 2016-12-21 JP JP2016247406A patent/JP2017079771A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2431600A1 (en) | Molecules with extended half-lives, compositions and uses thereof | |
JP2005501514A5 (en) | ||
JP6807132B2 (en) | Uses of IL-1 inhibitors and TNF antagonists partially combined with recombinant erythropoietin for the treatment of anemia | |
ES2686618T3 (en) | And anti-CD33 antibodies and use them to treat cancer | |
EP0602290B1 (en) | Antibody-conjugated Hepatitis B surface antigen and use thereof | |
AU2015296298A1 (en) | Flagellin-based agents and uses including effective vaccination | |
HRP20110334T1 (en) | Tgf beta 1 specific antibodies | |
JP2022106975A (en) | Engineered antibody compounds and conjugates thereof | |
JP2023538518A (en) | IL10Rb binding molecules and methods of use | |
JP2019142921A (en) | Generation of highly potent antibodies neutralizing lukgh (lukab) toxin of staphylococcus aureus | |
BRPI0406745A (en) | Parenteral formulations of peptides for the treatment of systemic lupus erythematosus | |
JP2023536654A (en) | IL10Ra binding molecules and methods of use | |
JP2023508047A (en) | Combination therapy using an IL-2 receptor agonist and an immune checkpoint inhibitor | |
HAVELL et al. | Production and characterization of anti-murine interferon-gamma sera | |
CN112552406B (en) | Anti-human CD73 antibody | |
CN112574313B (en) | anti-CD73 antibodies and uses thereof | |
AU2022207020A1 (en) | Anti-tigit antibody pharmaceutical composition and application thereof | |
CN115814105A (en) | Application of antibody drug conjugate, combined drug and application thereof | |
KR20210125847A (en) | The fusion protein comprising Feline granulocyte colony-stimulating factor and antigen binding fragments for serum albumin and use thereof | |
CN112175087A (en) | Bispecific antibody for resisting CD4 and TGF beta, pharmaceutical composition and application thereof | |
CN114667160A (en) | Immune tolerant elastin-like recombinant peptides and methods of use thereof | |
CN107106672B (en) | Monoclonal antibodies against muramyl peptides for the prevention and treatment of immune-mediated diseases | |
CN108601819B (en) | Amelioration of systemic sclerosis with death receptor agonists | |
Tučková et al. | Macrophage nitric oxide synthase (NOS) activation by Nocardia opaca fractions and 15‐and 56‐kD isolated antigens | |
WO2023212662A2 (en) | Compositions and methods for modulating antigen binding activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20211213 |